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Abstract of the Dissertation
Learning clinical outcomes from massive
observational data
by
Trevor Raymond Shaddox
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University of California, Los Angeles, 2016
Professor Marc Adam Suchard, Chair
Emerging national patient claims and electronic health record databases offer
a rich frontier for learning about treatment effectiveness and clinical decision
making. However, these resources present statistical and computational chal-
lenges commensurate with their promise, requiring innovative approaches for
practically and efficiently extracting meaningful results. In this dissertation, I
seek to address some of these challenges. First, I present a hierarchical model
for learning about the relationship between treatments and multiple related
adverse outcomes simultaneously, showing that this approach can reduce bias
in relative risk estimates. Second, I develop a novel minorization-maximization
(MM) algorithm for uncoupling the sequential Newton steps that arise within
the state of the art model fitting procedure for the conditional models popular
for observational studies, allowing faster, parallelized model fitting. Third, I
develop a birth-death model for treatment trajectories among patients with dia-
betes mellitus type II. In these sections, I discuss applications to observational
healthcare datasets, demonstrating how these methods work at scale.
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CHAPTER 1
Introduction: the challenge of large scale
observational healthcare studies
“Data Science" has found medicine. The integration of technology into medical
practice and record-keeping continues to transform medical research, giving
birth to interdisciplinary fields like biomedical informatics while simultane-
ously stimulating new, overlapping branches of biostatistics, computer science,
and epidemiology. The breadth of shareholders reflects the challenges and
promise of learning from observational healthcare data. Three main domains
define this area. The first centers on the data: its collection and concerns
surrounding its use. The second domain I will loosely call the informatics
infrastructure: how the data are stored and represented. Finally, the challenge
most relevant to this dissertation is modeling at scale: how we transform the
data into actionable knowledge.
1.1 The data
The first question that should arise in a discussion of learning from observa-
tional healthcare data is "What added value do large repositories of medical
data bring to medicine and public health?" Schneeweiss and Avorn [2005]
remind us that clinical trials cannot answer all important medical questions.
The marginal cost of gathering observational healthcare data is considerably
smaller for the same number of patients than for traditional modalities of
medical studies. Randomized trials require recruiting and maintaining patients.
In contrast, observational healthcare data is collected for largely non-scientific
purposes: billing or patient care. Using the data as a scientific resource is
largely data repurposing.
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Consequently, the size of these datasets dramatically dwarfs the datasets
actively collected for scientific analysis. Alone, this difference in scale is a
tremendous asset. For example, drug trials have limitations for detecting rare
adverse events. Enrolling thousands of participants, such trials are underpow-
ered for sufficiently rare events. If a drug passes clinical trials and is used by a
sufficiently large population, that population can help identify rare events. A
classical example of this is identifying risk for drug-induced torsade de points
[Poluzzi et al., 2009]. This condition is both extremely rare, less than 1/100,000,
and clinically significant, potentially resulting in cardiac death. Clinical trials
are unable to accurately estimate the risk of a given drug for producing torsade
de points without considerable cost, and observational data become the resource
of choice [Poluzzi et al., 2009].
It is meaningful to remark on the difference between efficacy and effective-
ness. Clinical trials focus on appropriately measuring efficacy, the theoretical
impact of a drug on a disease [Flay et al., 2005]. However, effectiveness, how
the treatment behaves in practice, may be clearer from observational studies,
which looks at “real" world settings [Flay et al., 2005]. This becomes muddled
when asking questions of causality, but we will try to separate the division of
efficacy and effectiveness from causal inference [Imai et al., 2008]. Especially as
clinical care organizations become more closely monitored for their collective
decision making, having the appropriate application of knowledge to clinical
action within the local setting becomes important [Barieri and Maistrello, 2009].
That is, clinical effectiveness becomes a question dependent on the local patient
community.
Clinical trials may be ethically unfeasible. Clinical equipoise reflects a
physician’s absence of preference among treatment choices: presented with
drug A or drug B, the physician is equally fine with using either. Clinical trials
rely on clinical equipoise. When it egregiously breaks down, a randomized trial
would be ethically wrong. For example, it might be concerning to randomize
patients to placebo when comparing the treatment effect of metformin to a new
anti-hyperglycemic medication in newly diagnosed diabetic patients. There are
corrections to the randomized clinical trial framework that help accommodate
this, such as non-inferiority trials, but the observational data do away with this
conflict, as well as far subtler, less-easily corrected ones, entirely.
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Married with these benefits are several challenges [Schneeweiss and Avorn,
2005]. These challenges stem predominantly from the fact that these data are
not collected for scientific study. When using observational data, the analyst
will be quite far removed from the data collection process, much more so than a
counterpart working on survey data, for example. This often means the analyst
has less control of the data contents and may be blind to what is both measured
or, critically, unmeasured in the data. For a simple example, smoking status is
sparsely represented in some observational healthcare data resources. In some
resources, this reflects the fact that is just not relevant for the collection agency,
and for others, it reflects a system-specific incomplete recording practice [Jick
et al., 2000].
Patient privacy is a serious concern that drives much legislative involve-
ment in observational health data. Mechanically, this can be problematic for
accessing datasets, but that is more annoyance than flaw. True concerns arise as
de-identified datasets have greater coverage, increasing the likelihood of signif-
icant patient overlap. Linking databases becomes desirable but is structurally
prevented.
Similarly, drop-out is a concern. While loss-to-follow-up is not unique to
observational studies, its presence is significant. Turnover rates for insurance
data can reach as high as 30% per year [Short et al., 2003, Schneeweiss and
Avorn, 2005]. This can be critical when considering the data as representative
of long-term observation.
Here, we will consider two main types of observational healthcare data.
First, electronic health records (EHR) data consist of the data stored by care
centers who deploy clinical information systems to facilitate patient care. In
theory, EHR data are very complete, since they represent the data important
to a clinician making decisions about patient care. A drawback of EHR data
is that they are largely geographically limited. For example, an EHR dataset
may reflect a single care location or a shared network of care locations. But,
these networks are relatively small on a national scale, raising questions about
generalizing results from single EHR systems. On the other hand, insurance
claims data often have larger catch basins for the patients represented and
may better represent communities historically excluded from clinical trials
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[Schneeweiss and Avorn, 2005]. However, these data have less granularity, and
what is represented is chosen because of financial considerations.
1.2 Informatics infrastructure
Following the highly public recall of rofecoxib and renewed concern about
drug safety, the U.S. Food and Drug Administration (FDA) Amendments
Act of 2007 required that the FDA use observational data in an automated,
reproducible approach to identify risks from medical interventions. Prior, the
standard for observational pharmacovigilance was spontaneous reports data
[Bennett et al., 2007]. To help address this pressing need, the Observational
Medical Outcomes Partnership (OMOP) emerged [Stang et al., 2010]. Built as a
public-private partnership among the FDA, academia, data owners, and the
pharmaceutical industry, OMOP sought to provide a transparent framework
for comparing drug safety study methodologies and evaluating drug safety
risk. The OMOP community highlights the second main component of research
with observational data: the considerable informatics infrastructure that must
exist to facilitate meaningful analysis.
1.2.1 The common data model
In mentioning the limitations of observational data above, Schneeweiss and
Avorn [2005] list one weakness of observational data as the diverse “grammars"
in which data are maintained. This concern is certainly valid, but the OMOP
community, and others like them, has already taken steps toward addressing
this issue. One of the achievements of the OMOP community was the creation
and implementation of a transparent common data model (CDM) [Stang et al.,
2010]. The CDM and the extract-transform-load (ETL) processes developed to
impose the CDM ensure integrity across longitudinal observational databases
(LODs) [Hartzema et al., 2013].
The goal for creating the OMOP CDM was facilitating reproducibility of
study designs across datasets using different terminologies. In the absence of a
CDM, a researcher must run studies tailored to database specific terminology.
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Largely, this means most studies only focus on a single database. Working
with multiple terminologies means developing multiple studies, and such du-
plication invites errors. Distinct terminologies preclude assurance that studies
applied to one dataset are identical to studies applied to other datasets. With a
CDM, the same analyses can evaluate different datasets without modification.
It follows directly that another benefit of a CDM is including multiple data
sources when performing research. This allows the consumers of research to
ask relevant, meaningful questions about the generalizability of results. The
OMOP community brought this issue to the forefront through their landmark
paper comparing studies across multiple data sources [Madigan et al., 2013].
The CDM is structured to accommodate studies on medication [Reisinger
et al., 2010]. The format of the CDM is patient-centric. For each patient, there is
a unique identifier that links all relevant data tables. Distinct tables hold non-
overlapping information about the patient’s health. For example the Drug Era
table contains spans of time during which a patient was exposed to a particular
product. Many different representations for a drug exist. One could report
the brand name, the generic name, or the ingredients. For the Drug Era table,
the CDM records the ingredients. Thus if a patient were on empagliflozin and
linagliptin, a single pill with two medications to treat diabetes mellitus, from
August 1, 2005 until July 5, 2006, this would register as two separate drug eras
for empagliflozin and linagliptin, each from June 19, 2005 until July 5, 2007. A
drug era is a combination of individual prescriptions or drug fills. For example,
if the same medication is refilled routinely at the end of its 30 day supply for 2
refills, this appears as a single 90 day drug era. OMOP uses a standard 30 day
persistence window, where if a new supply of the same medication is given
within 30 days of the termination of a previous supply, it is considered the
same era. For example, consider a patient who takes metformin for 60 days,
forgets to refill a prescription for 4 days and does not take any medication.
Then on the 5th day, that patient refills the prescription and continues taking
metformin for 90 days. With a 30 day persistence window, all of the medication
use actions result in a single 154 day drug era. The 30 day persistence window
helps buffer refill discontinuities. Other tables include a Condition Era table
for diagnoses and a Person table for patient demographic data.
While this illuminates the overall format for the CDM, we still need to
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demonstrate how the standardization occurs. This involves two goals: 1) trans-
lating from the native data representation to the CDM representation and 2)
providing accurate structure for relationships within the CDM [Reisinger et al.,
2010]. The CDM achieves the first goal by maintaining a dictionary of relation-
ships between native and CDM representation. This includes information from
such disparate data terminologies as the International Classification of Diseases,
Ninth Revision - Clinical Modification (ICD-9-CM), Systematized Nomencla-
ture of Medicine-Clinical Terms (SNOMED-CT R©), and Medical Dictionary for
Regulatory Activities (MedDRA R©). The CDM accomplishes the second goal by
encoding the relevant “is-a" relationships that represent how concepts relate.
For example, the relationship from the SNOMED-CT or Anatomical Therapeu-
tic Chemical (ATC) hierarchy present in the CDM would allow us to see that
rofecoxib, an ingredient in our Drug Era table, is a cyclooxegenase-2 (COX-2)
inhibitor.
Taking a native dataset and translating it to the CDM, the ETL process,
follows four steps [Reisinger et al., 2010]. First, we copy the data from the source
database to the appropriate CDM structure, placing the data in appropriate
tables. Next, we annotate each datum with the CDM designation. Third, we
aggregate data to produce the appropriate drug eras, dependent on our selected
persistence window. Fourth, we export the data, now transformed to the CDM,
to a relational database.
While this concludes the data processing, it is reasonable to wonder how
well such processing captures the native data representation. Overhage et al.
[2012] studied this question in the context of 10 observational datasets, in-
cluding both claims and EHR data. OMOP created two packages to test
transformation fidelity: the Observational Source Characteristics Analysis Re-
port (OSCAR), which produces simple summary statistics, and the Generalized
Review of OSCAR Unified Checking (GROUCH), which checks for anomalous
results in OSCAR [Overhage et al., 2012]. Unacceptable results that GROUCH
detects include, for example, abnormally large patient ages, negative era time,
and pregnancy in males, among many others. Although the ETL process
required substantial teams of different skills, including informaticists and clin-
icians, the process itself took at most 11 days. The conversion to the CDM
was largely complete, around 90% or higher, and accurate, as evaluated by
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GROUCH.
1.3 Modeling at scale
Armed with a wealth of promising clinical data structured to facilitate repro-
ducible research, the last step in learning from observational healthcare data
is the transition from data to meaningful, actionable inference. This is the
modeling step. Many factors enter into selecting how to model healthcare
events in this space. Madigan et al. [2011] unambiguously states that the central
challenge of drawing inference from observational healthcare data is confound-
ing, where identified associations between drugs and outcomes are fallaciously
given causal significance. However, while addressing confounding through
fidelity in modeling the underlying biology and clinical decision making is
critical, practical demands motivate some modeling choices over others. In
particular, the key modifier in this field is “at scale." Our datasets consist of
tens of millions of patients exposed to the full spectrum of medical products.
Coping with such massive resources requires considering the computational
demands.
1.3.1 Univariate studies
At the beginning of modern pharmacovigilance, the dominant approach to
identifying drug-outcome pairs of interest relied on disproportionality testing
[DuMouchel, 1999]. The general structure of this technique is a two-by-two
table, where the table is populated with the counts of patients who took the
drug or did not and had the outcome or did not. Then, some measure of
“interestingness" would evaluate the table, and “interesting" drugs would call
for further investigation [Madigan et al., 2011]. In part, this reflected the most
widely used data, reports from physicians of events that they thought were
suspicious. However, this technique also emerged in the setting of claims and
EHR data.
This method satisfies our second requirement for modeling “at scale."
Namely, it deals with dimensionality with ease, since the reported values are
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essentially just counts. Any statistical inference for these disproportionality
methods builds conclusions from four numbers. The weakness of this method
is dealing with confounding. For an example from [Madigan et al., 2011],
consider an anti-emetic drug. Further, suppose that this drug makes patients
susceptible to eye infections. If an attentive physician treats a patient on the anti-
emetic with a prophylactic antibiotic, this antibiotic will appear to be strongly
correlated with nausea, unless we control for the anti-emetic medication. In
this case, the sacrifice of confounding adjustment for performance produces
a spurious result. Frustratingly, this technique continues to be near or at the
cutting edge of drug safety surveillance [Huang et al., 2014].
1.3.2 Multivariate studies
Moving beyond univariate studies to more sophisticated methods represents
a “quantum jump in pharmacovigilance" [Hauben et al., 2005]. Methods that
have gained considerable traction for analyzing outcomes from observational
datasets include cohort, case-control, and case-crossover methods [Maclure,
1991, Rothman et al., 2008]. Of these, cohort methods remain popular for
controlling for confounding variables [Schneeweiss, 2014]. Cohort methods
help correct the shortcomings of the univariate disproportionality testing.
However, these methods may encounter difficulties accommodating the second
requirement for modeling with observational healthcare datasets: working at
scale. In response, other approaches have gained popularity.
Farrington [1995] proposes the self-controlled case series (SCCS) method in
order to estimate the relative incidence of rare drug-specific outcomes to assess
vaccine safety. Risk of an event is a function of exposure-specific effects and
patient-specific risks. For Farrington [1995], the exposures are vaccine delivery
time intervals; for us, the exposures are medical products. For many appli-
cations, including pharmacovigilance, we are only interested in the exposure-
specific effects. Estimating a per-person underlying rate of an outcome does
not help identify what drugs are harmful. The SCCS model allows us to avoid
estimating these unhelpful covariates, and we gain efficiency in estimating the
meaningful covariates.
Simply, in these conditional methods, each patient acts as his or her own
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control. To this extent, we only focus on the increased rate of an outcome
of interest when exposed to a drug compared to absence of exposure versus
looking at the overall rate of that outcome per patient. In essence, the patient
specific rate defines how many events we see for that patient, but we really just
care about how that rate changes under exposure to a treatment of interest.
To explain this more rigorously, we follow the discussion of Short et al.
[2011] and Farrington [1995]. We will use notation that is consistent with our
later use of this model. Consider events happening as a non-homogeneous
Poisson process. Let patients i = 1, . . . , N have a baseline risk eφi . Define a
period of observation as an era, indexed by k, and let lik be the time duration
of the era. In the absence of exposure, we model the events of patient i in era k
as Poisson(lik × eφi).
Next we add in drug exposures. Let j = 1 . . . J index the potential exposures,
with the parameters β = (β1, . . . , β J)′ measuring the instantaneous log relative
risks of treatment exposure, and let xik = (xik1, . . . , xikJ)′ where xikj indicates
exposure to drug j in era k for person i. The drug exposures multiplicatively
modulate the underlying instantaneous event intensity during constant drug
exposure era k. The number of ADEs in era k of patient i is now yik ∼
Poisson(λik) where λik = lik × eφi+x′ikβ. Conditional on the drug exposure xik,
the density of yik is
p(yik|xik) = e
−λik(λik)yik
yik!
(1.1)
For each person, the likelihood is
Li = p(yi|xi)
=∏
k
e−λik(λik)yik
yik!
=∏
k
e−lik×e
φi+x
′
ikβ(lik × eφi+x′ikβ)yik
yik!
= e−e
φi ∑k lik×ex
′
ikβ(eφi)∑k yik∏
k
(lik × ex′ikβ)yik
yik!
.
(1.2)
We condition on the total number of events ni = ∑k yik, the sufficient statistic,
to avoid estimating φi. We model the events in each ear as a non-homogeneous
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Poisson process, so the sum of the events per person also follows the Poisson
distribution:
ni|xi ∼ Poisson(eφi
Ki
∑
k
lik × ex′ikβ). (1.3)
For each person, the conditional likelihood is
Lci = p(yi|xi, ni)
=
p(yi|xi)
p(ni|xi)
=
e−eφi ∑k lik×e
x′ikβ(eφi)∑k yik ∏k
(lik×ex
′
ikβ)yik
yik!
e−e
φi ∑
Ki
k lik×e
x′ikβ
(eφi ∑
Ki
k lik×e
x′ikβ)ni
ni!
=
ni!∏k(lik × ex′ikβ)yik
yik!(∑
Ki
k lik × ex
′
ikβ)ni
.
(1.4)
Thus, by conditioning on the sufficient statistics, the baseline risk falls out of
the conditional likelihood of the data.
How does this conditioning statement improve modeling compared with an
unconditional model? The utility from conditioning arises emerges as improved
efficiency. Efficiency is a reflection of how well an estimator or design uses data
to produce a reasonable result. To compare the SCCS method with the cohort
method, we are interested in the relative efficiency, the ratio of the efficiency
measures for each method.
Returning to Farrington [1995], we can measure the relative asymptotic
efficiency of the SCCS method compared with the cohort method with the ratio
of the asymptotic variance of maximum likelihood parameter estimates (MLE).
To look at the asymptotic relative efficiency, consider N patients as before, each
exposed to 2 eras of length l1 and l2. In particular, we assume no exposure
happens during the first era, and we let an exposure to a single drug happen
for V individuals during the second era. In the SCCS model, the log likelihood
for these patients is
Lsccs (β) =
N
∑
n=1
[
yi2 xi2β− (yi1 + yi2) log
(
l1 + l2 ex
′
i2β
)]
. (1.5)
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For βˆsccs, the MLE, Farrington [1995] finds
var(βˆsccs) =
(l1 + l2eβ)2
(∑i yi1 + yi2)(l1l2eβ)
. (1.6)
To this, Farrington [1995] compares the unconditional cohort model. This has
Poisson rate eφ[l1 + l2eβx], where the patient specific rate φi is the same for all
patients. Under this model, the log likelihood is
Lcohort (β) =
N
∑
n=1
[
(yi1 + yi2)φ+ yi2βxi − eφ(l1 + l2eβx)
]
. (1.7)
For βˆcohort, the MLE for the cohort model, Farrington [1995] finds
var(βˆcohort) =
1
V(l2eφ+β)
(
1+
l2(VN )e
β
l1 + l2(1− VN )
)
. (1.8)
We compute the efficiency as
E =
var(βˆcohort)
var(βˆsccs)
=
1
V(l2eφ+β)
(
1+ l2(
V
N )e
β
l1+l2(1− VN )
)
(l1+l2eβ)2
(∑i yi1+yi2)(l1l2eβ)
(1.9)
The expected value of ∑i(yi1 + yi2) is Veφ[l1 + l2eβ] using the cohort model.
Therefore, we substitute and get the asymptotic efficiency as
E =
1
V(l2eφ+β)
(
1+ l2(
V
N )e
β
l1+l2(1− VN )
)
(l1+l2eβ)2
Veφ[l1+l2eβ](l1l2eβ)
=
1+ l2
V
N
l1+l2(1− VN )
eβ
1+ l2l1 e
β
.
(1.10)
Looking at this asymptotic efficiency, we can glean some intuition about how
11
the efficiency varies with dataset characteristics. As the proportion of treated
people VN declines, the relative efficiency declines. That is, for situations
where the exposure use is high, we see more efficiency in the SCCS method.
Furthermore, as the incidence of the outcome of interest decreases, we see
increase in relative SCCS efficiency. This is particularly noteworthy, since we
are frequently interested in rare outcomes. In summary, both of the situations
that boost the relative efficiency of SCCS apply to the problems of interest,
validating our use of conditional models in this setting.
An additional benefit of the SCCS model is that it reduces the study pop-
ulation. If we are interested in patients with a rare event, we just use the
patients in the dataset who have ever had that event. In datasets at the scale of
interest, rarely do we lack for patients. Often, the challenge is computationally
managing the patients we have. By limiting ourselves to the most informative
patients, we can mitigate the computational burden.
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CHAPTER 2
Hierarchical modeling of multiple outcomes
Clinical trials often lack power to identify rare adverse drug events (ADEs)
and therefore cannot address the threat rare ADEs pose, motivating the need
for new ADE detection techniques. Emerging national patient claims and
electronic health record databases have inspired post-approval early detection
methods like the Bayesian self-controlled case series (BSCCS) regression model.
Existing BSCCS models do not account for multiple outcomes, where pathology
may be shared across different ADEs. We integrate a pathology hierarchy
into the BSCCS model by developing a novel informative hierarchical prior
linking outcome-specific effects. Considering shared pathology drastically
increases the dimensionality of the already massive models in this field. We
develop an efficient method for coping with the dimensionality expansion by
reducing the hierarchical model to a form amenable to existing tools. Through
a synthetic study we demonstrate decreased bias in risk estimates for drugs
when using conditions with different true risk and unequal prevalence. We also
examine observational data from the MarketScan Lab Results dataset, exposing
the bias that results from aggregating outcomes, as previously employed to
estimate risk trends of warfarin and dabigatran for intracranial hemorrhage
and gastrointestinal bleeding. We further investigate the limits of our approach
by using extremely rare conditions. This research demonstrates that analyzing
multiple outcomes simultaneously is feasible at scale and beneficial.
2.1 Introduction
Adverse drug events (ADEs) pose a serious public health risk. While clin-
ical trials remain the gold standard for evaluating drug safety and efficacy,
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the emergence of massive healthcare repositories, in the form of longitudinal
observational databases (LODs), introduces a novel resource for asking and
answering drug safety questions. These databases contain insurance claims
and electronic health records, with time-stamped patient data that include
drug exposures and diagnoses. The scale of these datasets is remarkable, with
hundreds to thousands of observations on tens of millions of patients. These re-
sources can potentially support post-approval surveillance for ADEs, where we
can monitor the relative safety of drugs after they are clinically available. The
development of a common data model (CDM) for LODs through the Observa-
tional Medical Outcomes Partnership (OMOP) experiment facilitates statistical
methods implementation using these data to address pertinent questions about
health practices, including comparative drug safety [Overhage et al., 2012].
The OMOP experiment has demonstrated the value and efficacy of competing
analytical approaches [Stang et al., 2010]. While observational studies may be
vulnerable to variability of study design, and the OMOP community produced
the first steps toward systematic statistical evaluation of observational evidence
[Madigan et al., 2014].
Commensurate with its considerable promise, analysis of LODs presents
a significant statistical and computational challenge. Patients have different
levels of illness and compliance that are not readily identifiable from the LODs.
Observations are incomplete and inhomogeneous over time. In addition, the
scale of the data creates a massive, but extremely sparse, resource. Not only
are LODs massive in the number of patients recorded, they also contain the
full spectrum of medical products, interventions, and diagnoses. This scale
precludes many analytic approaches.
ADEs are clinical manifestations of specific pathologies. For example,
hypocoagulability affects the entire body, creating a general increased risk of
bleeding. However, the clinician will identify the results of hypocoagulability
by the anatomic location where a bleeding event occurs. If the bleeding occurs
in the brain, the diagnosis will be an intracranial hemorrhage. If the bleeding
occurs in the stomach, the diagnosis will be a gastric hemorrhage. The clinician
will identify the outcome but may not identify the pathology. The drug-specific
effect often occurs at the level of the pathology, but the identified ADEs appear
at finer granularity. Connecting outcomes and drugs without considering
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shared pathology ignores a crucial component of the pathophysiology.
Currently, most analytical approaches consider one outcome at a time, ignor-
ing relationships among the outcomes. In particular, we miss an opportunity
to "borrow strength" [DuMouchel, 2012] across outcomes where there is shared
pathophysiology. Dealing with multiple ADE outcomes remains of critical
importance to epidemiology and data mining [Thuraisingham et al., 2009,
DuMouchel, 2012]. DuMouchel [2012] and Crooks et al. [2012] approach this
problem by borrowing strength across outcomes to construct a multivariate
logistic regression.
A common method for avoiding multiple outcomes is aggregating all the
outcomes of interest into one overarching category, essentially considering
different outcomes as exchangeable. Selecting which outcomes are related
often follows directly from how clinicians codify diseases. For example, the
International Classification of Diseases version 9 (ICD-9) code 432 represents
“other and unspecified intracranial hemorrhage," of which 432.1 “subdural
hemorrhage" is a subtype. Using all 432.* ICD-9 codes would capture all the
subtypes of “other and unspecified intracranial hemorrhage" the ICD-9 con-
siders, essentially aggregating all subtypes under the 432 code. The OMOP
Standard Vocabulary encompasses multiple disease relationship representa-
tions, including the Systematized Nomenclature of Medicine-Clinical Terms
(SNOMED-CT) vocabulary. However, determining which outcomes are related
by shared pathology need not be limited to disease codes; the discretion of a
clinical expert should guide their selection.
Aggregating outcomes produces drug risk estimates that reflect a weighted
average of the risk for each outcome separately. This may introduce bias into
outcome-specific risks. Prevalence differences underscore this bias, with high
prevalence outcomes driving risk estimates. When considering outcomes with
low prevalence, we would like to combine information about them with closely
related common outcomes. However, aggregating these rare outcomes with
common ones overwhelms the drug-outcome specific relationship. Therefore,
we would like a way to treat similar outcomes as distinct while still respecting
their relatedness.
In this paper we move beyond focusing on one outcome at a time. Specifi-
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cally, we seek to reduce the bias that arises when we aggregate multiple, related
outcomes into one synthetic outcome. To do this, we develop a set of open-
source statistical tools relying on LODs structured according to the OMOP
common data model. We integrate a hierarchy of pathology and outcomes into
ADE detection.
2.2 The self-controlled case series (SCCS) model
2.2.1 SCCS framework
The most common approaches to analyzing outcomes from LODs include
cohort, case-control, and case-crossover methods [Maclure, 1991, Rothman
et al., 2008]. However, other approaches have gained popularity in recent
years. Farrington [1995] proposes the self-controlled case series (SCCS) method
in order to estimate the relative incidence of rare drug-specific outcomes to
assess vaccine safety. Simpson et al. [2013] and Suchard et al. [2013] use this
model successfully in ADE detection. A significant benefit of the SCCS model
is that it reduces the sample size to exposed patients experiencing at least one
adverse event. Adverse event risk is a function of drug-specific effects and
patient-specific risks, including underlying conditions. However, we are only
interested in the drug-specific effects, and the SCCS model allows us to focus
our statistical power on estimating these covariates of interest. These benefits
make the SCCS model ideal for pharmacovigilance. A major limitation of the
SCCS remains its formulation around one outcome at a time, a situation we
will rectify by splicing our hierarchical model into an SCCS framework.
The SCCS model assumes that ADEs arise according to an inhomogeneous
Poisson process. For a given LOD, let P count the number of outcome types
we are considering, and let p = 1, . . . , P index these outcomes. For a given
drug j, let Qj equal the number of outcomes where at least one patient who
has that outcome consumed that drug. Let jp = 1, . . . , Jp index the drugs
where there is at least one exposure to a patient with outcome p, such that
J1, . . . , JP count the total number of drugs observed in the exposure set for each
outcome. Parameters β = (β1, . . . ,βP)′ where βp = (βp1, . . . , βpJp)′ measure
the instantaneous, unknown, log relative risks given exposure for each drug
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with respect to each outcome. Under the model, let patient i = 1, . . . , N for
outcome p = 1, . . . , P have a baseline risk eφip . We consider drug eras as
intervals of exposure over which the drugs a patient takes remains constant.
Let the drug exposures multiplicatively modulate the underlying instantaneous
event intensity λikp during constant drug exposure era k.
We consider drug eras as intervals of exposure over which the drugs a
patient takes remain constant. This aspect of the OMOP CDM requires special
attention. We use the OMOP CDM 4 definition of a drug era. A drug era is a
combination of individual drug exposures, such as individual prescription fills.
For example, if the same medication is refilled routinely at the end of its 30
day supply for 3 refills, this appears as a single 90 day drug era. Our constant
eras are intervals of time where patients remain on the same combination of
medication. For example, consider a patient who takes drug A from July 5,
2009 through July 20, 2009 and drug B from July 10, 2009 to July 17, 2009. Three
distinct drug eras emerge: one era from July 5 to July 9; another from July 10
to July 17; and the last era from July 18 to July 20.
Let Kip be the total number of drug eras for person i in condition p. Follow-
ing the notation of Suchard et al. [2013] and Simpson et al. [2013], the intensity
arises as λikp = e
φip+x
′
ikpβp , where xikp = (xikp1, . . . , xikpJp)
′ and xikpj indicates
exposure to drug j in era k for outcome p. The exposure duration for exposure
era k of patient i is likp. The number of ADEs in era k of patient i for outcome p
is yikp ∼ Poisson(likp × λikp). The SCCS method conditions on the total num-
ber of events for a particular outcome nip = ∑k yikp that a patient experiences
over her total observation period. For multiple outcomes, (ni1, . . . , nip) remain
sufficient statistics for the subject’s baseline risks (φi1, . . . , φip). By conditioning
on these statistics, the baseline risks fall out of the conditional likelihood of
the data regardless of their correlation and hence greatly reduce the number of
parameters to estimate:
N
∏
i=1
P
∏
p=1
P
(
yip|xip, nip
)
=
N
∏
i=1
P
∏
p=1
P
(
yip|xip
)
P
(
nip|xip
)
∝
N
∏
i=1
P
∏
p=1
Kip
∏
k
 ex′ikpβp
∑
Kip
k′ lik′pe
x′
ik′ pβp
yikp . (2.1)
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Taking the log of Equation (3.1) yields the log-likelihood under our model
L (β) =
N
∑
n=1
 P∑p=1
 Kip∑
k=1
(
yikp x′ikpβp
)
− nip log
 Kip∑
k=1
likp e
x′ikpβp

that forms only part of our objective function of interest. Specifically we work
in a Bayesian framework and choose to specify a prior distribution for the
covariates.
Bayesian techniques are ideal for pharmacovigilance, succinctly capturing
clinical prior knowledge of drug safety, and are common in the field, as seen in
Curtis et al. [2008], Madigan et al. [2011]. Furthermore, the Bayesian approach
mitigates many of the challenges of massive sparse data. Simpson et al. [2013]
reduce overfitting under a maximum likelihood approach by assuming a prior
over the drug effect parameter vector, constructing a Bayesian SCCS. We assume
a priori that most drugs are safe and therefore assume a prior that shrinks the
parameter estimates toward 0.
2.2.2 Disease hierarchies
To analyze a group of related outcomes, we follow DuMouchel [2012] in
framing our approach as a hierarchical multivariate regression, where the
specific outcomes are related under their shared pathology. Each adverse
event has a separate representation of each shared drug, a drug-outcome effect
estimate. We rely on our Bayesian perspective and project that idea onto
multiple ADE outcomes by extending our prior.
In the original Bayesian SCCS formulation applied to LODs, there can exist
upwards of Jp ∼ 10, 000 drug covariates. Multiple outcomes exacerbate this
extreme dimensionality. Namely, we need to compute J = ∑Pp=1 Jp covariates,
roughly P-fold more covariates. To cope with this ultra high dimensionality, we
model the effects of the same drug across outcomes hierarchically. We represent
each drug-outcome effect as inheriting from a drug-pathology effect. We extend
the prior structure of the original Bayesian SCCS model by using a hierarchical
prior that shares information across regression coefficients (β1j, . . . , βQj j) that
measure the association of a single drug j across all Qj outcomes where drug j
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appears in the records. The drug-level precision is τd, and the pathology-level
precision is τp.
Not all drugs need be present across all outcomes. Therefore, we scale the
prior precision for each drug by the number of outcomes in which the drug
appears as a non-zero covariate. For example, if drug A appears among the
patients with intracranial hemorrhage and gastric hemorrhage, while drug B ap-
pears only among patients with gastric hemorrhage, we seek to compensate for
this mismatch by scaling the universal drug-level precision when approaching
each outcome specific risk estimate. Specifically, we model
µj
β1j β2j · · · βQ j j
µj ∼ Normal
(
0, τp
)
, and
β1j, . . . , βQj j ∼ Normal
(
µj, Qj · τd
)
.
(2.2)
2.2.3 Computational swindle
As described, the hierarchical model imposes greater dimensionality, a more
cumbersome log-likelihood, and a host of new parameters to track, suggesting
that we will require new inference equipment that scales for LODs. However,
a redefinition of parameters demonstrates that our more complex model eas-
ily compresses into a form that allows for inference with the existing high
performance SCCS tools of Suchard et al. [2013]. We concatenate outcome
specific event counts vectors y˜ = (y1,y2, . . . ,yP)′ and time of exposure vec-
tors l˜ = (l1, l2, . . . , lP) into new vectors representing the adverse events and
exposure times across all outcomes.
In practice, we take our data, a set of event counts and drug exposures, for
each outcome and add an outcome-specific tag to each of the drug exposures.
That is, each drug exposure now has an associated outcome. For example, if
we look at bleeding events, with outcomes intracranial hemorrhage and gastric
hemorrhage, and drug warfarin, a covariate would be warfarin-intracranial
hemorrhage or warfarin-gastric hemorrhage. Considering β˜ = (β1,β2, . . . ,βP),
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covariates for the same event are consecutive. We construct a new design matrix
X˜ ,
X˜ =

X1 0 · · · 0
0 X2 · · · 0
... . . .
...
0 0 · · · XP
 .
This design matrix is necessarily block diagonal, since the outcome-specific
covariates are not represented in other outcomes. For example, the warfarin-
intracranial hemorrhage covariate is not present among the data on patients
who have gastric hemorrhage events. Given this structure, the resulting log-
likelihood is
L (β) =
N
∑
i=1
[ Ki
∑
k=1
(
y˜ik x˜′ikβ˜
)− ni log
( Ki
∑
k=1
l˜ik ex˜
′
ikβ˜
)]
. (2.3)
Under this reindexed representation, log-likelihood (2.3) matches the ex-
pression in Suchard et al. [2013], enabling us to recycle existing computational
infrastructure. Furthermore, each Xp is extremely sparse, and the computa-
tional approach of Suchard et al. [2013] efficiently represents and computes over
sparse systems. While creating X˜ increases the dimensionality, it is a sparse
expansion, mitigating the computational demand. Thus, we can leverage the
extant sparse computing solutions to evaluate this more sophisticated model,
without drastically increasing the computational demand.
2.2.4 Maximum a posteriori estimation using cyclic coordinate descent
Given the reformulation, the changes to the univariate Bayesian SCCS frame-
work remain in the prior. For notation, we consider the set Gj of covariates
representing the same drug across all conditions we consider. The cardinality
of Gj is Qj. Let Gj{p} be this set excluding βpj. We consider the induced prior
distribution,
p(βGj) =
∫
p(βGj |µj)p(µj)dµj. (2.4)
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Taking the log of the integrand and recalling that all coefficients are independent
given the pathology effect yields:
log
[
p(µj)
]
+ log
[
p(βGj |µj)
]
=
[
f1(τp)−
τp
2
(µj − 0)2
]
+ f2(τd)− Qjτd2 ∑g∈Gj(βg − µj)2

= f3(τp, τd)−
τp
2
(µj − 0)2 −
Qjτd
2 ∑g∈Gj
(βg − µj)2
= f3(τp, τd)− 12
(Q2j τd + τp)µ2j − 2Qjτdµj ∑
g∈Gj
βg
+Qjτd ∑
g∈Gj
β2g
 .
In this construction, f1(τp), f2(τd), and f3(τp, τd) are constants with respect to
µj and Gj employed to simplify notation.
Completing the square to perform the integral returns
log
[
p(βGj)
]
= f4(τp, τd)− 12
Qjτd( ∑
g∈Gj
β2g)−
(Qjτd ∑
g∈Gj
βg)2
Q2j τd + τp
 , (2.5)
where f4(τp, τd) is a constant with respect to µj and Gj that remains after
integrating over µj.
The implementation of Suchard et al. [2013] uses cyclic coordinate descent
(CCD) to find the maximum a posteriori (MAP) estimates through optimizing
the model log posterior P(β) = L(β) + log[p(β)]. Our approach amounts to
regularized regression, for which CCD has been heavily employed [Friedman
et al., 2010, Wu and Lange, 2008]. CCD circumvents the need to invert the full
Hessian at each step [Wu et al., 2009b]. At each CCD iteration, the updates
are a function of the log-likelihood gradient ∂L/∂βpj and Hessian ∂2L/∂β2pj
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as well as the penalty gradient ∂log[p(β)]/∂βpj and Hessian ∂2log[p(β)]/∂β2pj.
A single Newton step is taken along each coordinate and proves extremely
efficient when X is sparse [Genkin et al., 2007, Suchard et al., 2013].
Working in the CCD framework, we require the gradient and the Hes-
sian contributions to the log-likelihood and log-priors. Fortunately, the log-
likelihood remains unchanged using our computational swindle. However, the
penalty component does change under the hierarchical model, with both the
gradient and the Hessian a function of the pathology precision. The forms of
the penalty components in the Newton steps are
∂log(p(βpj|βGj{p}))
∂βpj
= −Qjτdβpj +
(Qjτd)2(∑g∈Gj βg)
Q2j τd + τp
and
∂2log(p(βpj|βGj{p})
∂βpj
2 = −Qjτd +
(Qjτd)2
Q2j τd + τp
.
(2.6)
2.2.5 Hyperparameter selection:
We use cross-validation based on the predictive log-likelihood of the hold-out
set to select the hyperparameters τp and τd. Suchard et al. [2013] use a log-scale
grid search that is computationally expensive even with only a single parameter.
When we add a second parameter, this method becomes impractically slow.
The additional parameter τp increases overall computing cost by an order of
magnitude. However, it remains desirable to use cross-validation to select both
τd and τp.
To help overcome this burden, we turn to Genkin et al. [2007] in implement-
ing an "autosearch" for hyperparameter selection. We start with an initial guess
and then increase or decrease our guess by one log unit until we have bracketed
the maximum of the hold-out set predicted log-likelihood. Then we compute
a quadratic approximation to the predicted log-likelihood. The maximum of
this approximate surface becomes our estimate. To find both hyperparameters,
we alternate between them, fixing one and finding the conditional maximum
of the other, and then fixing to that new conditional solution and finding
the conditional maximum of the other. We continue this process until both
previous and proposed hyperparameters are within an order of magnitude.
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We prefer using this flexible tolerance method to a fixed tolerance method, in
which finding the appropriate fixed tolerance would be difficult considering
the log-scale of the search space.
2.3 Demonstration:
2.3.1 Synthetic study: biased risk estimates
To evaluate the bias that arises when using aggregated outcomes, we simulate a
small dataset with three conditions of interest. For the first and third conditions,
the prevalence of these diagnoses is extremely low, with only 20 and 10 patients
having these conditions, respectively. For the second condition, the prevalence
is much higher, with 1000 patients present in our hypothetical dataset. We
expose these synthetic patient groups to 10 drugs. Two drugs are positively
associated with all conditions. However, the risk for these two drugs varies
drastically among the three groups. In particular, the two dangerous drugs
present a log relative risk of 0.5 for the first, rare condition, a log relative risk
of 1 for the second common condition, and a log relative risk of 2 for the third,
rare condition.
In our simulations, we first draw a patient-specific underlying risk from a
Normal(-1,0.5) distribution. Then, for each patient, we uniformly select between
1 and 10 observations, or drug exposure eras, as well as an observation length
per observation. In each observation, we assign between 1 and 10 drugs to
the patient. For each drug, we know the log relative risk for the given event.
Armed with the underlying risk rate as well as the drugs per observation, we
compute the overall risk rate for each observation and draw from a Poisson
distribution with that intensity to get the event count during that observation.
We compare the marginal estimates of the relative risks in both the aggre-
gated data situation and using our hierarchical model. We first run our analysis
considering all conditions exchangeable, extracting one risk estimate per drug.
Effectively, when we aggregate data, the log relative risk among these three
populations becomes a weighted average risk estimate. In Figure (2.1 a) we
see that the analysis of the aggregated data slightly underestimates the log
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Figure 2.1: Mode estimates and 95% bootstrap confidence intervals (gray) of the log relative
risk for each drug and their simulated relative risk (black) across two conditions
with different prevalence. The first 10 covariates represent the estimates from one
condition with a prevalence of 20 patients; the second 10 represent estimates from
the condition with high prevalence, affecting 1000 patients; and the last 10 covari-
ates represent a second condition with low prevalence, affecting 10 patients. Using
the multiple outcomes in an aggregated approach (a) produces less appropriate
estimates than the hierarchical outcomes approach (b).
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relative risk of the dangerous drugs in the large population. In the 20 patient
and 10 patient populations, the method seriously overestimates and underesti-
mates, respectively, the log relative risk of the dangerous drugs. In contrast,
the estimates from modeling these outcomes together under a hierarchical
structure avoid this problem. Separate risk estimates for each drug-outcome
pairs demonstrate much less bias, as seen in Figure (2.1 b).
We compare the model fitting times for each of these datasets, including
cross-validation and bootstrapping with 200 replicates. For the cross-validation,
we averaged the predicted log-likelihood over 6 permutations of the 10-fold
sampling of the data. Fitting the aggregated dataset took 5 seconds, and
the cross-validation variance was 0.1. Using the autosearch cross-validation
method, fitting the hierarchical model took 9 seconds. We also fit the model
using the grid search cross-validation method. Specifically, we used a 10 by 10
grid ranging from 10−4 to 105 for both τ−1p and τ−1d . Using this grid, fitting the
model took 32 seconds. The results from the autosearch, with starting estimates
of 100, produced estimates of τ−1p and τ−1d at 1.1 and 2.2; the results from the
grid search produced estimates of τ−1p and τ−1d at 100 and 1.
The difference between the estimates for τ−1p from the autosearch method
and the grid-search method is noteworthy. The autosearch method finds a
value beyond a grid point of 100. This results from two effects. First, both
the autosearch and grid-search estimates may be sensitive to fitting parameter
choices, like the number of permutations over which to average. This reflects
the relatively flat topology of the predictive log-likelihood in this small dataset,
where chance selections of data for cross-validation can move our perceived
apex. We remedy this partly by averaging over multiple data permutations.
Second, this difference underscores the inability of the grid method to adjust
resolution as needed. The grid-search method is bound by our decision of grid
size. Resolving the method using a finer grid is computationally daunting. The
autosearch method avoids this problem, adjusting resolution as needed without
the computational tax. However, the difference we see between the search
methods in this case fails to appreciably change the estimated relative risks,
with no risk estimates changing by more than 0.015. This result highlights the
stability of our risk estimates to different hyperprior estimates.
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2.3.2 Real world study: warfarin and dabigatran
The standard for outpatient anticoagulation is warfarin, an inhibitor of vita-
min K metabolism. Clinically, warfarin is difficult to use, requiring frequent
laboratory tests to identify its sensitive, patient-specific dosing. Alternatives
to warfarin present an opportunity for improving anticoagulation care. In
2009, a randomized, controlled, noninferiority trial suggested that dabigatran
etexilate has a comparable treatment effect to warfarin [Connolly et al., 2009].
Furthermore, the manufacturer claims that dabigatran requires less clinical
attention than warfarin to find the appropriate dose. Although this trial also
found grossly similar risk profiles for dabigatran and warfarin, there were
notable differences. In particular, warfarin posed a greater overall risk of
major bleeding. However, dabigatran posed a significantly elevated risk of
gastrointestinal hemorrhage (GIH). Among the worst outcomes for patients on
anticoagulation therapy with warfarin is intracranial hemorrhage (ICH). The
rate of this ADE among dabigatran patients was one third that of warfarin
patients. Thus, for one ADE, dabigatran appears to increase risk; for another, it
appears to be safer. Many concerns about this trial have surfaced [Charlton and
Redberg, 2014]. New events of interest from the trial emerged later [Connolly
et al., 2010]. Reilly et al. [2014] produced better dose-risk trade-off results.
Subsequent clinical trials have reexamined the risk of major bleeding events.
The results of these trials are equally inconclusive, with greater transfusion
needs among dabigatran treated patients counterbalanced by lower intensive
care stay and lower mortality [Majeed et al., 2013].
We contribute to this debate by considering a real world equivalent of the
simulated study above. We want to use our hierarchical model to tease out
the risk profiles for both warfarin and dabigatran while reflecting the shared
pathology of bleeding events. Thus, we consider each of these outcomes under
our hierarchical model. Furthermore, we explore what would happen if we
aggregated these data, considering GIH and ICH exchangeable.
To perform these studies, we examine the MarketScan Lab Results (MSLR)
dataset, maintained by the Reagan-Udall Foundation Innovation in Medical
Evidence Development and Surveillance project. This dataset comprises 1.5
million patient lives. We depend on the OMOP common data model version 4
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Figure 2.2: Mode estimates and 95% bootstrap confidence intervals for the effect of dabigatran
(light gray) and warfarin (dark gray) on gastrointestinal hemorrhage (GIH) and
intracranial hemorrhage (ICH), compared to an aggregated outcome where GIH
and ICH are exchangeable.
for representation of concepts of interest. To examine GIH and ICH, we select
all patients who experienced a diagnosis that the OMOP common data model
version 4 considered a subset of GIH or ICH. There are 37,909 patients who
had GIH and 2,893 patients who had ICH.
Figure (2.2) demonstrates our results. Grossly, three trends appear. First,
we see that warfarin presents a lower risk for GIH than dabigatran. Second,
this risk pattern reverses for ICH. This replicates trends previously found in
the literature. Third, we see that considering these outcomes as exchangeable
seriously masks the ICH estimates. The larger population of GIH patients
overwhelms the analysis.
We again consider the computation time for each analysis, including cross-
validation and bootstrapping. We used 200 replicates for the bootstrapping and
averaged over 20 permutations of the cross-validation sampling data. Analyzing
the GIH and ICH datasets independently took 124 and 9 seconds producing
single variance estimates of 5.28 and 29.06 using one dimensional autosearch
with a starting value of 0.1. Analyzing the aggregated dataset using one
dimensional autosearch required 111 seconds and produced a single variance
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estimate of 1.1. Under the hierarchical model, the 10 by 10 log grid-search
approach with a range of 10−3 to 106 took 4735 seconds and produced estimates
of τ−1p and τ−1d of 1 and 0.1. Using the two dimensional autosearch approach
with an initial value of 0.001 took 2163 seconds and produced estimates of τ−1p
and τ−1d of 4.15 and 0.18.
2.3.3 Real world study: extreme prevalence differences
In some cases, we want to evaluate the risk of extremely rare events, which
may contain very little information about each drug risk pair. To explore what
happens in this situation, we return to the MarketScan Lab Results (MSLR)
dataset. Specifically we focus on two conditions: chronic gastrojejunal ulcer
with hemorrhage and obstruction (CGJUHO) and vomiting blood (VB). Both
of these diagnoses inherit from the OMOP common data model version 4
representation of upper gastrointestinal bleeding. We produce risk estimates
from modeling these two categories as exchangeable, and we contrast our
results when treating these two categories hierarchically. To construct our
patient population, we select all patients who have had either of those diagnoses
delivered in an inpatient, emergency department, or outpatient setting. There
are only 24 patients with CGJUHO; there are 16,062 patients with VB. We
consider the entire spectrum of drugs for both conditions.
Using 10-fold cross-validation with the predictive log likelihood averaged
over two permutations and the one dimensional autosearch with an initial
value of 0.1, analyzing the CGJUHO data alone produces a single prior variance
estimate of 0.060 in 4 seconds, and analyzing the VB data produces a single prior
variance estimate of 0.0076 in 200 seconds. The aggregated model required
200 seconds to find the point estimates, with a variance estimate of 0.0077.
Under the hierarchical model, using a 10 by 10 log-scale grid of variance
values ranging from 10−8 to 101, we find τ−1p and τ−1d maximize the predicted
log-likelihood at 0.01 and 0.0001, respectively. Using the autosearch method,
we find the optimal τ−1p and τ−1d to be 0.019 and 0.00017, respectively. The
autosearch required 10,500 seconds; the grid search required 209,500 seconds.
Although we consider all drugs for each condition of interest, it is most
interesting to look at the drugs that are present among both the set of patients
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with CGJUHO and the set of patients with VB. The 288 drugs that fit this
criterion have non-trivial hierarchies. From Figure (2.3), we see that under
the hierarchical model, the condition-specific risk estimates are very close.
Furthermore, the estimates under the hierarchical model are very close to those
under the aggregated model.
Ostensibly, this result undercuts the purpose of the hierarchical modeling.
However, there are notable differences between this study and both the previous
simulated study and the warfarin and dabigatran study. In this case, CGJUHO
had drastically fewer patients than VB. Given the stark contrast in prevalences,
it is reasonable for the very common condition to dominate the risk estimates of
both the hierarchical and aggregated models. This suggests that the hierarchical
model will correct for risk estimate bias as long as the prevalence differences
between two conditions are not extreme. But, in the case of extreme prevalence
differences, the results will be similar to aggregating the data. While the greedy
iterative two dimensional autosearch approach greatly reduces computational
time relative to the exhaustive search, it is still faster to compute a single
hyperprior. Therefore, the differences in prevalence should guide the user in
determining whether using the hierarchical model is warranted in her analysis.
2.4 Discussion
In this work, we have developed a novel hierarchical framework for analyzing
multiple outcomes in the setting of massive observational data. We have
demonstrated that we can easily restructure this framework to leverage extant
inference tools that mitigate the dimensional explosion of analyzing multiple
outcomes. Furthermore, we have shown the value of such a framework in
better discrimination of dangerous drugs and in better risk identification in
small populations.
There are challenges in working with observational data [Ryan, 2013]. Inter-
database variation in reported risk estimates can be considerable [Madigan
et al., 2013]. Bias in the recording of the data percolates through all analyses.
Assumptions regarding the uniformity of treatment and diagnosis decisions
among physicians are almost certainly incorrect. The time-invariant risk as-
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sumption underlying the SCCS model is almost certainly false for some drug
and disease pairs.
However, the quantity of data from observational healthcare datasets will
not decrease, and the promise of these data remains strong. One hope for
success in this field is to channel the information present in these databases
into a framework that optimally allows for signal detection and noise reduction.
One method for achieving this goal effectively is to integrate more biological
and medical knowledge into the models. The simple hierarchical model of
disease, which matches both disease biology and clinical perspectives of disease,
is one modest example of such structural knowledge motivating advances in
modeling.
In the future, hierarchical modeling can extend beyond diseases. Drugs
also follow a natural hierarchical structure. Physicians and pharmacologists
use drug classification heavily to group medications with similar modes of
action together. These classification systems form a natural framework for
understanding drug risk. The post-approval withdrawal of Vioxx (rofecoxib)
has been one of the highest profile cases of a drug with insidious side effects.
The medical community did not fully appreciate the cardiac effects of rofecoxib
until after the drug had been released to the market. It is thought that the
entire class of COX-2 inhibitors puts patients at risk for cardiovascular events
[Cannon and Cannon, 2012]. While traditional NSAIDs inhibit COX-1 and
COX-2, COX-2 selective inhibitors have negligible effects on COX-1. One could
consider the hierarchical structure of the drugs following a similar model
as suggested here. Each of the drugs could inherit a class-specific risk. For
example, all of the COX-2 inhibitors would share a greater risk for MI than the
COX-1 inhibitors. This would allow the model to capture class specific effects
that are currently inefficiently estimated independently.
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Figure 2.3: Mode estimates of the log relative risk for each drug for a common, rare, or
aggregated outcome. The common outcome is vomiting blood (VB), dark gray
triangles. The rare outcome is chronic gastrojejunal ulcer with hemorrhage and
obstruction (CGJUHO), light gray circles. The aggregated outcome is CGJUHO
or VB, black squares. The estimates for CGJUHO and VB rely on the hierarchical
structure.
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CHAPTER 3
Minorization-maximization (MM) methods for the
SCCS model
Adverse drug events (ADEs) remain a serious public health risk. Identifying
dangerous drugs from emerging national patient claims and electronic health
record databases is a non-trivial statistical challenge. Specifically, fitting models
in the context of datasets with tens of thousands of covariates and millions of
observations always perches on the edge between computationally expensive
and intractable. New techniques for optimization in this setting add to the
arsenal of strategies that can push sophisticated, meaningful modeling toward
feasibility. Here, we develop a Minorization-Maximization (MM) algorithm in
the context of the Bayesian self-controlled case series (SCCS) regression model.
We take two minorization transformations of the SCCS likelihood to produce
parameter separation in the surrogate. Although this increases in the number
of iterations required for convergence, it transforms a sequential iterative
algorithm into a parallel iterative algorithm. Looking to an observational
dataset examining the relationship of diclofenac and gastrointestinal bleeding
with 940 drug exposure covariates and more than 5.5 million distinct drug eras,
we find that parallel processing with the decoupled Newton steps improves
model fitting 10 fold. We further demonstrate how acceleration with augmented
Newton steps and quasi-Newton approximation can improve speedup to 17
and 28 fold above the sequential algorithm. These results underscore the value
MM algorithms can bring to high-dimensional regression problems in setting
of massive observational data.
32
3.1 Introduction
Questions of drug safety and comparative effectiveness hold considerable inter-
est for the medical community and present novel challenges for the statistical
community. While randomized controlled trials remain the gold standard, the
emergence of massive healthcare data repositories presents a new setting in
which to learn about drug exposures [Stang et al., 2010]. These data resources
are often in the form of longitudinal observational databases (LODs), with mil-
lions of patients represented in insurance claims and electronic health records.
These resources have the scope and diversity to identify rare events and to
address medical product use ’in the wild.’ Here we will frame our work in
terms of adverse events (AEs).
Traditionally, learning about drug exposure risks relies on cohort, case-
control, and case-crossover methods [Maclure, 1991, Rothman et al., 2008].
The self-controlled case series (SCCS) designed by Farrington [1995] has gained
popularity in recent years [Simpson et al., 2013] and [Suchard et al., 2013].
Conditioning on the presence of at least one adverse event for each subject
reduces the sample size to exposed patients and eliminates questions of appro-
priate case and control matching criteria. Additionally, under this conditioning
argument, the patient-specific risks, including underlying conditions, disappear,
reducing the problem to estimating drug-specific effects.
Analysis of LODs presents a significant computational challenge. These
data track millions of patient observations including thousands of medical
products, a massive and extremely sparse resource. Learning about associations
between all products and specific AEs, while controlling for simultaneous
exposures, is a compelling goal. Generalized linear models (GLMs) with
unknown parameter regularization or Bayesian priors provide a fruitful and
popular framework [Madigan et al. 2011]. However, naive implementation
to find maximum a posteriori (MAP) point-estimates, often with multivariate
Newton’s method slows to a crawl with millions of outcomes and thousands of
predictors. Within the SCCS model, mode finding remains the computational
bottleneck. Simpson et al. [2013] and Suchard et al. [2013] avoid the taxing high-
dimensional matrix inversion component of Newton’s method and implement
mode finding through cyclic coordinate descent (CCD). This is a standard
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strategy to mode finding in regularized regression [Friedman et al., 2010, Wu
and Lange, 2008]. One of the drawbacks of this optimization strategy is that
the Newton steps are inherently serial.
In this paper, we develop a method to decouple the CCD Newton steps,
and, by doing so, create a parallelizable optimization procedure. We do this by
leveraging the minorization-maximixation (MM) algorithm [Hunter and Lange,
2000]. The MM algorithm replaces directly evaluating the objective function of
interest with computing over a surrogate function. When using the MM algo-
rithm, the objective function of interest often satisfies some property that the
original objective function did not. For us, this property is local independence
of the covariates. We also demostrate two methods for accelerating optimiza-
tion with this MM algorithm. We compare these strategies by looking at an
observational healthcare dataset with 5.5 million drug eras and 940 distinct
exposures, focusing on the risk of the painkiller diclofenac on gastrointestinal
bleeding.
3.2 Methods
3.2.1 SCCS
SCCS is a cases-only design, where each individual controls for her own
exposure, removing individual-specific effects. The method compares AE rates
between exposed and unexposed time-intervals . The SCCS model assumes
that AEs arise according to an inhomogeneous Poisson process. For j = 1 . . . J
drugs under consideration, the parameters β = (β1, . . . , β J)′ measure the
instantaneous, unknown, log relative risks given exposure. Under the model,
let patient i = 1, . . . , N have a baseline risk eφi . We consider drug eras as
intervals of exposure over which the drugs a patient takes remains constant.
Let the drug exposures multiplicatively modulate the underlying instantaneous
event intensity λik during constant drug exposure era k. That is, following
the notation of Suchard et al. [2013] and Simpson et al. [2013], the intensity
arises as λik = eφi+x
′
ikβ, where xik = (xik1, . . . , xikJ)′ and xikj indicates exposure
to drug j in era k . The exposure duration for exposure era k of patient i is
lik. The number of AEs in era k of patient i is yik ∼ Poisson(lik × λik). The
34
SCCS method conditions on the total number of events for a particular outcome
ni = ∑k yik that a patient experiences over her total observation period. By
conditioning on these statistics, the baseline risk falls out of the conditional
likelihood of the data and greatly reduces the number of parameters to estimate:
N
∏
i=1
P (yi|xi, ni) =
N
∏
i=1
P (yi|xi)
P (ni|xi) ∝
N
∏
i=1
Ki
∏
k
(
ex
′
ikβ
∑Kik′ lik′e
x′
ik′β
)yik
. (3.1)
Taking the log of Equation (3.1) yields the log-likelihood under our model
L (β) =
N
∑
n=1
{[
Ki
∑
k=1
(
yik x′ikβ
)− ni log
(
Ki
∑
k=1
lik ex
′
ikβ
)]}
. (3.2)
Bayesian techniques are ideal for pharmacovigilance, succinctly capturing
clinical prior knowledge of drug safety, and are common in the field, as seen in
Curtis et al. [2008], Madigan et al. [2011]. Furthermore, the Bayesian approach
mitigates many of the challenges of massive sparse data. Simpson et al. [2013]
reduce overfitting under a maximum likelihood approach by assuming a prior
over the drug effect parameter vector, constructing a Bayesian SCCS. We assume
a priori that most drugs are safe and therefore assume a prior that shrinks the
parameter estimates toward 0. Thus, Equation (3.2) forms only part of our
objective function of interest. For each covariate, we have
β j ∼ Normal (0, τ) (3.3)
for precision τ. Equivalently, this transforms our optimization problem into a
penalized regression problem, where we employ an L2 norm. For a deeper un-
derstanding of the connections between penalized regression and our Bayesian
formulation, Kyung et al. [2010] is a notable resource.
The implementation of Suchard et al. [2013] uses cyclic coordinate descent
(CCD) to find the maximum a posteriori (MAP) estimates through optimizing the
model log posterior P(β) = L(β) + log[p(β)]. The common idea behind CCD
algorithms is to update β by cycling through β j. Each update is a function of the
unidirectional log posterior gradient ∂P(β)∂β j and Hessian
∂2P(β)
∂β2j
. This approach
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is widely used for regularized regression [Friedman et al., 2010, Wu and Lange,
2008]. Preference for the CCD algorithm over traditional multivariate Newton’s
method stems from avoiding the Hessian inversion [Wu et al., 2009a].
Within each univariate Newton step, there are choices for the size of one-
directional step. Rather than iterate one-dimensional updates to convergence
within a cycle, many prefer taking a single Newton step [Genkin et al., 2007,
Wu and Lange, 2008, Zhang and Oles, 2001]. Here, we use the implementation
of Simpson et al. [2013] that follows from Genkin et al. [2007], Zhang and Oles
[2001]:
∆β j = −
∂
∂βl
(L(β) + log[p(β)])
∂2
∂βl
2 (L(β) + log[p(β)])
. (3.4)
We reiterate the fitting procedure from Suchard et al. [2013] in Algorithm 1,
with a terser representation to highlight the structure we will contrast with
subsequent algorithms. Following Genkin et al. [2007] and Suchard et al. [2013]
we declare convergence when the sum of the absolute change in Xβ from
successive iterations falls below 1× 10−6.
Algorithm 1 Cyclic coordinate descent (CCD) algorithm for fitting the Bayesian
self-controlled case series model. This highlights the serial nature of the
algorithm. In particular, we see β, the J-dimensional vector of regression
coefficients, as both the target over which we wish to maximize the log-posterior
and the focus of our serial updates.
Initialize: β = 0
while Xβ has not converged do
for j ∈ {1, . . . , J} do
Compute ∂∂β j (L(β) + log[p(β)]) and
∂2
∂β j
2 (L(β) + log[p(β)])
Update β j = β j + ∆β j
Update Xβ and ∑Kik=1 lik e
x′ikβ ∀i
end for
end while
3.2.2 MM algorithm: a philosophy
The popular expectation-maximization (EM) algorithm is a critical tool for situ-
ations where closed-form score equations in maximum likelihood estimation
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are absent [Dempster et al., 1977]. Statisticians have come to realize that the EM
algorithm is a special case of the broader class MM (minorization-maximization
or majorization-minimization) algorithms [Lange et al., 2000, Hunter and Lange,
2004, Wu and Lange, 2008].
The MM algorithm is not a recipe for solving an optimization problem, but
a framework for constructing algorithms. The main idea of the MM approach
is to avoid maximizing a difficult function by working with an easier surrogate
function. Consider an objective function f (x) which we want to maximize.
We seek a surrogate function that will minorize f . The surrogate function of
interest g(x|xm) minorizes f (x) if it shares the value of f (xm) and for all other
x, g is below f . That is, we require
f (xm) = g(xm|xm), and
f (x) ≥ g(x|xm),x 6= xm. (3.5)
In the MM algorithm, the goal is to move the surrogate function uphill,
relocate the point of tangency, and recompute the surrogate function. For many
MM approaches, this means actually maximizing the surrogate function
xm+1 = argmax(g(x|xm)) (3.6)
and reconstructing a surrogate function g(xm+1) using the point of tangency
f (xm+1) = g(xm+1|xm+1).
However, a step in the right direction accomplishes the same goal. A
Newton step along the surrogate function would move in the right direction
xm+1 = xm −
∂g
∂xm
∂2g
∂x2m
. (3.7)
This new point xm+1 is sufficient for creating a surrogate function g(xm+1),
using the point of tangency f (xm+1) = g(xm+1|xm+1).
Under the dual problem of minimization, the surrogate function we seek
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will be one that majorizes f . Majorization shares the structure of minorization.
The function h(x|xm) majorizes f (x) if it shares the value f (xm) and for all
other x, h is above f . More precisely, we require
f (xm) = h(xm|xm)
f (x) ≤ h(x|xm),x 6= xm. (3.8)
Under the minimization formulation, we follow the same procedure as with
maximization, driving the surrogate function downhill.
3.2.3 Exploring MM techniques
The marginal utility of the MM algorithm hinges on the selection of the surro-
gate function. There are many ways to find a majorizing or minorizing function
for a given problem of interest; the key is selecting the surface to accomplish
a particular goal. We will discuss two well-known MM tools, which we use
together in our implementation. For a concave function, the simple tangent line
satisfies the requirements of a majorizing function [Hunter and Lange, 2004].
Specifically, for a concave f (x), the tangent line
g(x|xm) = f (xm) + d f (xm)(x− xm) (3.9)
satisfies the majorizing requirements. That is, we have g(xm|xm) = f (xm) and
g(x|xm) ≥ f (x) ∀x 6= xm. When using this approach, finding argmin(g(x|xm))
is obviously problematic. This will not be a concern for us, as we will use this
technique in conjunction with others.
The second method relies on Jensen’s Inequality, which states that a secant
through a convex function lies above the arc of the function bounded by the
two points of intersection [Hunter and Lange, 2004]. For a convex function
f (t), this is
f (∑
i
αiti) ≤∑
i
αi f (ti). (3.10)
We take this inequality and transform it into a recipe for dealing with inner
products within convex functions. First, we can transform x with a linear
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function c′x for some c. Setting αi = cixmi /c′xm gives the majorization
g(x|xm) =∑
i
αi f
(
ci
αi
(xi − xmi) + c′xm
)
. (3.11)
Again, we can see that g(x|xm) fulfills the MM criteria: g(x|xm) = f (c′x) and
g(x|xm) ≥ f (c′x) ≤ ∀x 6= xm.
3.2.4 Developing an MM algorithm for the SCCS model
We consider both of these tricks in the context of the self-controlled case series
likelihood. The goal when constructing our surrogate surface is decoupling
the covariates. That is, we preserve the Newton step framework from CCD
implementation, and we want the Newton steps along each coordinate to be
locally independent. Looking at Equation (3.2), we see that the numerator
contribution ∑Kik=1
(
yik x′ikβ
)
is already decoupled. Therefore, we focus on
separating variables out of the log denominator term in Equation (3.2). That
is, we want to apply MM transformations to the log denominator term so that
each Newton step relies on the other coordinates only through the previous
iteration’s solutions. We do this by taking two MM transformations of the log
likelihood denominator.
For clarity, we specify notation for the sums that appear the numerator and
denominator contributions for each patient i. The sum that appears in the
numerator is
Ti =
Ki
∑
k=1
(
yik x′ikβ
)
, (3.12)
and, the sum from the denominator is
Di =
Ki
∑
k=1
lik ex
′
ikβ. (3.13)
Under this new notation, our log likelihood becomes
L (β) =
N
∑
n=1
Ti − ni log (Di) . (3.14)
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We begin constructing our minorizing surface to Equation (3.14) by address-
ing the outer logarithm. Using the tangent line inequality from Equation (3.9),
we see that
− log (Di) ≥− log (Dmi )−
1
Dmi
(Di − Dmi ) (3.15)
where
Dmi =
Ki
∑
k=1
lik ex
′
ikβ
m
. (3.16)
Checking the minorizing constraint
L (β) ≥
N
∑
i=1
{
Ti + ni
[
− log (Dmi )−
1
Dmi
(
Ki
∑
k=1
lik ex
′
ikβ − Dmi
)]}
(3.17)
we see that we have an appropriate minorization. We can confirm the tangential
requirement
L (βm) =
N
∑
i=1
{
Tmi + ni
[
− log (Dmi )−
1
Dmi
(
Ki
∑
k=1
lik ex
′
ikβ
m − Dmi
)]}
. (3.18)
Using the tangent line technique allows us to cope with the log term at each
iteration, but the covariate updates would still be coupled. There remains an
inner product within the exponential, and we need to decouple this term. We
return to Equation (3.11), recognizing that ex is a convex function. Again, we
define notation to simplify the exposition. Let
Sik = lik ex
′
ikβ (3.19)
so that
Smik = lik e
x′ikβ
m
. (3.20)
Note that
Ki
∑
k=1
Sik = Di. (3.21)
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With this notation and using the result of Equation (3.11), we see that
Sik ≤
J
∑
j=1
αje
xikj
αj
(
β j−βmj
)
Smik (3.22)
where
αikj =
|xikj|p
∑Jh=1 |xikh|p
(3.23)
for some integer p. For indicator X the choice of p is inconsequential, and we
have
αikj =
xikj
zik
(3.24)
for zik the count of drugs present in era k for patient i. Using the results of both
MM techniques together, we have the full MM surface
Q(β|βm) =
N
∑
i=1
{Ti + ni [− log (Dmi )
− 1
Dmi
(
Ki
∑
k=1
J
∑
j=1
αikje
(
xikj
αikj
(
β j−βmj
))
Smik − Dmi
)]} (3.25)
or
Q(β|βm) =
N
∑
i=1
{Ti + ni [− log (Dmi )
− 1
Dmi
(
Ki
∑
k=1
J
∑
j=1
xikj
zik
e
(
zik
(
β j−βmj
))
Smik − Dmi
)]}
.
(3.26)
We see that Q(β|βm) satisfies the two requirements. That is,
L (β) ≥ Q(β|βm), and
L (βm) = Q(βm|βm).
(3.27)
Most importantly, we see that the covariates are decoupled.
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3.2.5 Newton steps in the MM approach
Within the MM framework, we keep the strategy of updating with Newton
steps. Rather than maximize the surrogate function, we take a single Newton
step along each covariate to advance our position. To obtain the Newton’s
steps, we require both the partial derivative and unidirectional Hessian for
each covariate. The partial derivative of the surrogate function for covariate l is
∂Q(β|βm)
∂βl
=
N
∑
i=1
{
Ki
∑
k=1
yik xikl − niDmi
Ki
∑
k=1
αikj
xikl
αikj
e
(
xikj
αikj
(
β j−βmj
))
Smik
}
(3.28)
or, equivalently,
∂Q(β|βm)
∂βl
=
N
∑
i=1
{
Ki
∑
k=1
yik xikl − niDmi
Ki
∑
k=1
xikle
(
zik
(
β j−βmj
))
Smik .
}
(3.29)
When evaluated at our current location,
∂Q(β|βm)
∂βl
∣∣∣∣
βl
m
=
N
∑
i=1
{
Ki
∑
k=1
yik xikl − niDmi
Ki
∑
k=1
xiklSmik
}
. (3.30)
Similarly, the local curvature is
∂2Q(β|βm)
∂βl
2 =
N
∑
i=1
− ni
Dmi
{
Ki
∑
k=1
zikxikle
(
zik
(
β j−βmj
))
Smik
}
. (3.31)
Evaluating this curvature at our current location gives
∂2Q(β|βm)
∂βl
2
∣∣∣∣
βl
m
=
N
∑
i=1
− ni
Dmi
{
Ki
∑
k=1
zikxiklSmik
}
. (3.32)
The regularization component of the Newton step remains the unchanged from
the CCD implementation, so we do not show it here.
As we see in Equations (3.30, 3.32), the gradient and Hessian components
of our Newton steps for a particular βl rely only on β j j 6= l through the
constants βm. Thus, we have succeeded in our main goal for employing the
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MM algorithm: decoupling our updates to the covariates. Our change to βml is
now
∆mβml = −
∂
∂βl
(Q(β|βm) + log[p(β)])
∂2
∂βl
2 (Q(β|βm) + log[p(β)])
∣∣∣∣
βl
m
. (3.33)
We modify the fitting procedure from Suchard et al. [2013] shown in Algorithm
1 in our new MM algorithm shown in Algorithm 2. Again, we declare conver-
gence when the sum of the absolute change in Xβ from successive iterations
falls below 1× 10−6.
Algorithm 2 MM algorithm for fitting the SCCS model. This highlights the
parallel steps of the algorithm. In particular, we see the three parallelized
targets for computation.
Initialize: m = 0
Initialize: βm = 0
while not Xβ converged do
In parallel compute ∂∂β j (Q(β|βm) + log[p(β)]) and
∂2
∂β j
2 (Q(β|βm) +
log[p(β)]) and update βm+1j = β
m
j + ∆
mβmj
In parallel compute Xβ
Atomically add ∑Kik=1 lik e
x′ikβ ∀i
m = m + 1
end while
Multi-core implementation
Now that we have decoupled the Newton steps, we can move away from the
serial iterative approach of CCD toward a parallel iterative implementation.
We expose three targets for parallelization.
3.2.5.1 Decoupled update
First, each Newton step or augmented Newton step can proceed in parallel.
Each update is independent between covariates. Therefore, we can assign
each update as a separate tasks to computing elements. The work per thread
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becomes
βm+1l = β
m
l −
∑Ni=1
{
∑Kik=1 yik xikl − niDmi ∑
Ki
k=1 xiklS
m
ik
}
+ ∂∂βl
(log[p(β)])
∑Ni=1− niDmi
{
∑Kik=1 zikxiklS
m
ik
}
+ ∂
2
∂β2l
(log[p(β)])
. (3.34)
3.2.5.2 Matrix-vector multiplication
The CCD approach efficiently updates Xβ by incrementing with each partial
step. After a Newton step for covariate j,
Xβ = Xβ+ ∆β jXj . (3.35)
In this setting, we are not required to recompute Xβ. However, this advantage
breaks down when using decoupled updates. We may simultaneously update
a group of covariates in β. Waiting after these steps to iteratively update Xβ
would negate the benefits of working in parallel.
Therefore, we no longer update Xβ with each step, but rather recompute
after updating β. This matrix-vector multiplication is amenable to paralleliza-
tion. We allocate each Xkβ as the parallelized task, with each Xkβ handled
independently.
3.2.5.3 Sum of exponentials
We can also compute
Dmi =
Ki
∑
k=1
lik ex
′
ikβ
m
(3.36)
in parallel for each i ∈ {1, . . . , N}. However, there is a notable caveat. For
updates to Dmi by k, there is a race condition, where updates from separate
eras for the same patient try to access the same partial sum. To account
for this, we atomically add lik ex
′
ikβ
m
for every k to Dmi . These sums D
m
i are
independent between different i, allowing the majority of these updates to
occur simultaneously.
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MM with acceleration
A well-known side effect of the MM algorithm is bloating of the iteration count
[Lange, 1995]. Each Newton step is conservative; we could move further up the
surface than the surrogate function permits. The result is slow convergence.
Many have tried to address this problem by developing acceleration techniques,
tricks that allow the MM step to be larger.
One straightforward approach to accelerating an MM algorithm is to double
the size of the MM step. That is, instead of updating
βm+1l = β
m
l + ∆
mβmj (3.37)
we update
βm+1l = β
m
l + 2 ∗ ∆mβmj , (3.38)
following Lange [1995] and Lange and Wu [2008]. This approach nullifies the
MM guarantee of ascent. For some problems, experience dictates that this
violation is not practically significant [Lange and Wu, 2008]. When this is
used absent regularization, doubling the MM step is equivalent to halving
the Hessian. We take this idea and apply it to the regularized setting, but we
would prefer to preserve the guarantees of the MM algorithm.
We extend this approach by dividing each of our unidirectional MM Newton
Hessian values by a factor φ ≥ 1. Now, we update
βm+1l = β
m
l −
∂
∂βl
(Q(β|βm) + log[p(β)])
∂2
∂βl
2 (
1
φQ(β|βm) + log[p(β)])
. (3.39)
After completing MM Newton steps for each covariate, we recompute the
log posterior density. If L(βm) > L(βm+1), we recognize that the augmented
Newton step was too ambitious. We could discard or accept this step, but we
choose to accept it here. This moves our position to the other side of the zenith.
However, we reset φ = φ2 , ensuring that our next step is more conservative. We
always decrease the augmentation factor. At worst, this pushes φ to 1. This
ensures that we drive the optimization uphill, even if we take a small number
45
of inappropriate steps. Since we already compute many components of the log
likelihood after a full cycle through β, the marginal cost to check for uphill
movement is minimal.
Algorithm 3 MM algorithm for fitting the SCCS model, similar to the one
shown in Algorithm 2. Here we include updating the augmentation factor φ.
Initialize: m = 0
Initialize: φ = φ0
Initialize: βm = 0
while not Xβ converged do
In parallel compute ∂∂βl (Q(β|βm) + log[p(β)]) and
∂2
∂βl
2 (
1
φQ(β|βm) +
log[p(β)]) and update βm+1j = β
m
j + ∆
mβmj
In parallel compute Xβ
Atomically add ∑Kik=1 lik e
x′ikβ ∀i
m = m + 1
if L(βm) + log[p(βm)] > L(βm+1) + log[p(βm+1)] then
φ = φ2
end if
end while
MM with quasi-Newton acceleration
A class of techniques for acceleration that also preserve the ascent guarantee are
quasi-Newton methods, and these are useful for accelerating MM algorithms
[Zhou et al., 2011]. The unifying idea of quasi-Newton methods is the use
of secant approximations. We develop our quasi-Newton acceleration closely
following Zhou et al. [2011].
We begin by considering Newton’s method in the context of root finding
for 0 = β − F(β). Following Zhou et al. [2011], F(β) is an algorithm map.
In the context of the SCCS model, F(β) is the resulting position from a cycle
of uncoupled Newton steps along the MM surface tangent at β. Newton’s
method solutions for root finding proceed as
βm+1 = βm − [I − dF(βm)]−1[βm − F(βm)],
where the Hessian matrix dF(βm) may be challenging to invert. Quasi-Newton
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methods avoid inverting dF(βm) by substituting a low rank secant approxima-
tion M . With M in hand, we could substitute (I −M ) for (I − dF(βm)) and
compute the easier (I −M )−1.
We consider U = (um−q, . . . ,um) and V = (vm−q, . . . ,vm), matrices of the
q most recent u and v vectors where um = F(βm)− βm and vm = F(F(βm))−
F(βm). Here, the secant requirements are Mum = vm. Relying on Proposition
1 from Zhou et al. [2011], we observe that M = V (U ′U )−1U ′ provides our
secant approximation to dF(βm). Our quasi-Newton update is
βm+1 = βm − [I − V (U ′U )−1U ′]−1[βm − F(βm)].
Finding the optimal q is not obvious. For different problems, the q that produces
the fewest iterations to convergence may vary [Zhou et al., 2011].
3.3 Demonstration
3.3.1 Comparing steps graphically
We begin with a tiny synthetic study to compare the MM steps graphically.
With a microscopic dataset of two patients and two drug exposures, we can
easily visualize the log posterior. On this surface, we plot the steps that our
optimization methods take to attain the maximum in Figure (3.1). Specifically,
we plot the CCD steps and the MM approach with no augmentation factor
(φ = 1). Both algorithms start at the origin, and each point represents the
position after a full traversal through β. We specify the prior variance as λ = 1.
For clarity in the graphic, we limit the iterations to 4. At 4 iterations, the CCD
method converges to the true optimum. However, the MM approach without
acceleration does not.
3.3.2 Diclofenac and gastrointestinal bleeding
Non-steroidal anti-inflammatory drugs (NSAIDs) are a cornerstone of pain
management, providing both anti-inflammatory and analgesic action. They
are commonly used in management of osteoarthritis and rheumatoid arthritis,
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Algorithm 4 MM algorithm for fitting the Bayesian self-controlled case series
model using the quasi-Newton approximation.
Initialize: m = 0
Initialize: βm = 0
Update β1 = β0 + ∆0β0
Compute u = β1 − 0 and add to set U
for p ∈ (2, . . . , q− 1) do
Update βp = βp−1 + ∆p−1βp−1
Compute u = βp − βp−1 and add to set U
Compute v = u and add to set V
end for
Update βq = βq−1 + ∆q−1βq−1
Compute v = βq − βq−1 and add to set V
while Xβ not converged do
Update βm = βm−1 + ∆m−1βm−1
Compute u = βm − βm−1 and add to set U
Update βm+1,(MM) = βm + ∆mβm
Compute v = βm+1 − βm and add to set V
Compute M = U ′(U − V )
Compute βm+1,(QN) = βm + VM−1U ′(βm − βm− 1)
if L(βm+1,(MM)) + log[p(βm+1,(MM))] > L(βm+1,(QN)) +
log[p(βm+1,(QN))] then
Update βm+1 = βm+1,(MM)
else
Update βm+1 = βm+1,(QN)
end if
end while
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Step comparison
l
l Start
MM
CCD
Figure 3.1: Step comparison between the Cyclic Coordinate Descent (CCD) and minorization-
maximization (MM) without acceleration (φ = 1) using our toy two dimensional
dataset. For each method, we limit the iterations to 4, showing how far each
progresses in the same number of iterations. The CCD approach converges after
4 iterations; the MM approach does not. The common starting point for both
approaches is (0,0), shown with an open circle, and each point represents the
position after a full traversal through β.
among other conditions [Hawkey et al., 1998]. This class of medications
includes naproxen and ibuprofen, common over-the-counter medications, as
well as diclofenac, a more potent variety available with prescription. Among
the most common adverse events associated with these drugs are events related
to the gastrointestinal (GI) system [Hawkey et al., 1998, Lanas, 2010]. Minor
adverse events from these medications include nausea and abdominal pain.
However, more serious adverse events can follow from NSAID use as well. GI
bleeding is among the most common serious adverse events associated with
NSAIDs.
We contribute to the risk estimates of diclofenac for GI bleeding by con-
sidering it in the context of our longitudinal healthcare datasets. We want to
compare our MM approaches with the CCD method fitting the SCCS model
on GI bleeding events among users of diclofenac. To perform these studies,
we examine the MarketScan Lab Results (MSLR) dataset, maintained by the
Reagan-Udall Foundation Innovation in Medical Evidence Development and
Surveillance project. This database contains time-stamped patient data, in-
cluding laboratory results, drug exposures, and diagnoses, deidentified to
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compliance with the Health Insurance Portability and Accountability Act of
1996 (HIPAA), comprising 1.5 million patient lives. The MSLR dataset includes
both inpatient and outpatient records.
The development of a common data model (CDM) through the Observa-
tional Medical Outcomes Partnership (OMOP) experiment facilitates statistical
methods implementation using these data [Stang et al., 2010]. The CDM allows
us to address pertinent questions about health practices, including comparative
drug safety, by standardizing data concept representation across resources
[Overhage et al., 2012]. Standardization takes the native representation in a clin-
ical data set of concepts like medication ingredients and diagnosis definitions,
such as International Classification of Diseases version 9 (ICD-9), and translates
them to a common representation. This facilitates consistent and reproducible
analysis across datasets; we can apply the same analyses to different data
resources, without having to recode our approach to accommodate dataset-
specific variations. We depend on the OMOP CDM version 4 for representation
of concepts of interest.
One aspect of the OMOP CDM version 4 requires special attention. We use
the OMOP CDM 4 definition of a drug era. A drug era is a combination of
individual prescriptions or drug fills. For example, if the same medication is
refilled routinely at the end of its 30 day supply for 2 refills, this appears as
a single 90 day drug era. OMOP uses a standard 30 day persistence window,
where if a new supply of the same medication is given within 30 days of
the termination of a previous supply, it is considered the same era. For
example, consider a patient who takes metformin for 60 days, forgets to refill a
prescription for 4 days and does not take any medication. Then on the 5th day,
that patient refills the prescription and continues taking metformin for 90 days.
With a 30 day persistence window, all of the medication use actions result in
a single 154 day drug era. The 30 day persistence window helps buffer refill
discontinuities.
We select all patients who experienced a diagnosis that the OMOP common
data model version 4 considered a subset of GI bleeding and who were exposed
to diclofenac. There are N = 120, 034 such patients. To control for the other
medications that may contribute to risk for GI bleeding, we include all other
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drug exposures. In the MSLR dataset, this population used J = 940 distinct
drugs. Over all of these patients, there are K = 5, 681, 213 distinct drug eras.
We use cross-validation based on the predictive log-likelihood of the hold-
out set to select the prior variance 1τ . Suchard et al. [2013] use a log-scale grid
search that is computationally expensive even with only a single parameter. To
help overcome this burden, we turn to Genkin et al. [2007] in implementing an
“autosearch" for hyperparameter selection. We start with an initial guess and
then increase or decrease our guess by one log unit until we have bracketed
the maximum of the hold-out set predicted log-likelihood. Then we compute a
quadratic approximation to the predicted log-likelihood. The maximum of this
approximate surface becomes our estimate. For this problem, our estimated
1
τ is 1.21. We only perform this cross-validation once using the CCD fitting
approach, and this computational cost does not enter into our calculations. For
all following performance comparisons, we pre-specify this prior variance. We
find the point estimate of the log relative risk for Diclofenac in this population
is 0.17 with a bootstrap 95 % confidence interval of [0.02, 0.26].
3.3.2.1 Parallelization
To take advantage of all of our parallelization opportunities, we turn to Amazon
Web Services. For all of our timing comparisons, we elect to use 36 core,
compute-optimized, Intel Xeon E5-2666v3, 60 GiB memory, EBS-only instances.
We test each of the parallelization tasks using 1, 2, 4, 8, 16, and 32 threads. To
measure performance gain from parallelization alone, our baseline speed is the
MM algorithm with φ = 1 using no parallelization. The speedup as a function
of parallelization appears in Figure (3.2).
The speedup from parallelization alone in the context of the MM algorithm
follows a similar pattern for both the decoupled Newton steps and the Xβ
computation. For both of these tasks, the relative gain in speed plateaus around
6 fold using 16 cores. Of the full fitting time in the non-parallelized (single
core) implementation, 83% of time is spent in either the decoupled Newton
steps or the Xβ computation, with only 15% of time is spent summing the
exponentials. Therefore, it is reasonable that the overall speedup of the MM
algorithm from parallelization tracks with the speedup from the decoupling
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Figure 3.2: Convergence time and fold speedup for each parallelization task as well as total
mode-finding time for the MM implementation without acceleration over different
thread counts. The open symbols represent the single core times, and the closed
symbols represent the times at each core count shown on the axis. The fold speed up
relative to the single core times is above the symbols. The speedup for the decoupled
Newton steps and the Xβ computation both plateau at just above 6 fold speed-up
around 16 threads. Since these dominate the computational load, the total time
follows a similar pattern. The atomic addition of exponentials outperforms these
calculations with a maximum speedup of over 17 fold at 32 cores.
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and the Xβ computation.
It is somewhat surprising that the atomic summing of exponentials signif-
icantly outperforms the decoupled Newton steps and the Xβ computation.
This process showed in excess of 17 fold speedup using 32 threads. Using the
full 36 cores did not improve the performance. In fact, using 36 cores was
slightly slower than using 32 cores. This is helpful when looking at Figure (3.2),
where it appears that the performance improvement is strictly increasing with
the number of cores used.
3.3.2.2 Acceleration
We first turn to the performance of the augmented Newton step acceleration.
Considering φ ∈ {1, 2, 4, 8, 16, 32}, we see that the time to convergence is
not monotonic in φ. For φ = 1, we have the non-accelerated MM algorithm.
Increasing to φ = 2 slows down the convergence rate. However, between 4 and
16, the number of iterations required for convergence decreases by roughly a
factor of three. The greatest improvement over the MM algorithm appears at
φ = 4, where 51 iterations produce convergence.
Similarly, we can look at the performance of the quasi-Newton acceleration,
and we see that the number of iterations is not perfectly related to the order
of Newton approximation q. The greatest improvement over the non-quasi-
Newton MM algorithm appears at q = 2, where only 32 iterations produced
convergence. Beyond q = 2, the effect of the quasi-Newton approach fluctuates.
3.3.2.3 Time
Finally, we compare the raw fitting time of the CCD approach with the MM al-
gorithm, considering the non-accelerated version as well as the two acceleration
methods. For the acceleration methods, we cherry-pick the best performing
settings as shown above. This helps capture the best-case scenario for speedup.
The CCD fitting time is the standard, requiring 83 iterations and 195 seconds.
We report the performance of the other methods as fold speed-up relative to
this time. The simple MM algorithm produces up to 10 fold speedup, despite
needing an additional 65 iterations. The quasi-Newton acceleration with q = 2
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Figure 3.3: We compare the fitting time for the MM with φ = 1, MM with φ = 4, and MM
with quasi-Newton acceleration with q = 2 fitting procedures with parallelization
(shown as symbols) to the CCD fitting time, shown as the horizontal line. We
report the performance as fold speedup, shown in the printed values beneath the
symbols versus the CCD algorithm.
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boosts the performance to 17 fold speedup versus the CCD fitting time, needing
just 32 iterations for convergence. The augmented Newton steps with φ = 4
produces the best speed-up, improving model fit time more than 28 fold with
51 iterations.
3.4 Discussion
In our two dimensional toy example, we see the challenge that the MM algo-
rithm presents. Each of the MM Newton steps with φ = 1 is excruciatingly
more conservative than the CCD steps, which visually converges to the optimal
point within two full updates. This captures how the MM Newton step and
the CCD Newton steps differ. This also allows us to see how the acceleration
choices discussed here ameliorate this situation. In particular, guessing φ = 4
or using quasi-Newton with q = 1 in this problem produces updates that
qualitatively replicate those of the CCD Newton steps. This helps explain how
these correct for the conservative MM Newton steps.
Comparing the plain MM algorithm with the CCD approach, we see a
notable decrease in cost per iteration, even without parallelization. Using CCD,
the cost per iteration is roughly 2.3 seconds. For the MM algorithm, this drops
to 0.8 seconds per iteration. This difference gives us an estimate of how much
iteration bloating in the MM approach we can tolerate. Using these values, we
break even at roughly 3 fold more iterations from the MM algorithm.
Recognizing when the MM approach produces faster results than CCD, or,
conversely, when it slows model fitting, is critical. For some problems, the MM
surrogate function may force our updates to be considerably more conservative
than CCD. By identifying the computational cost break-even point, we can pivot
from one approach to the other. This is particularly relevant for dynamically
determining the procedure to use as a function of the local hardware. If the
iteration count for the MM approach mildly exceeds the break-even point on a
32 core machine, the MM approach will likely be faster when leveraging all the
parallelization opportunities. On the other hand, the same situation presented
on a dual core laptop may make CCD the best choice. These comparisons
are likely unreasonable for single model fitting events. However, if we are
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fitting multiple models serially, within a cross-validation, bootstrapping, or
Markov chain Monte Carlo framework, it might be reasonable to adjust the
fitting algorithm on the fly.
Considering the augmented Newton step acceleration approach, the fact
that we guess φ = 4 well in toy problem raises more questions than answers.
One of the drawbacks of our approach is finding the initial step augmentation
value φ. Guessing a poor value may lead to considerably longer time to
convergence. Ideally, we would like to have a better method for selecting φ.
Searching through the space of φ is not reasonable for a single fitting of the
model. However, this becomes more appealing in a setting where a model
may be fit multiple times. For example, we could double the initial φ at each
model fitting, starting with φ = 1. The efficiency gain from using a good φ
might offset the inefficiency of searching for appropriate φ as the number of
serial uses increased. Alternatively, we see that φ = 4 helps the initial MM
Newton step match with the size of the initial CCD step. We could extend this
observation. If we take one full CCD step as well as one MM Newton step with
φ = 1, we could estimate φ from the length of the CCD update and the length
of the MM update. With this as our initial guess, we can proceed with the step
halving as appropriate if we overshoot the zenith.
Turning to the quasi-Newton acceleration, the efficiency fluctuation around
q is nominally surprising. Intuitively, the higher q, the better the secant ap-
proximation should be. In practice, this is known to not be so simple [Zhou
et al., 2011]. As with finding φ, selecting the best q is not obvious. Zhou et al.
[2011] offer little guidance on how to find the optimal q, suggesting that it is
problem-specific. Reflecting our experience with selecting φ, it is possible to
imagine learning the best q as part of a sequence of model fittings.
The quasi-Newton acceleration with the best q requires the fewest iterations
for convergence among all the approaches shown hear. While this reflects well
on this approach, we should be cautious when comparing this count to the
others. For each quasi-Newton step, we are effectively cycling through β twice.
Additionally, we take q cycles through β before beginning the quasi-Newton
steps. Therefore, the quasi-Newton iterations substantially underestimate the
amount of work done to achieve an update if they are directly compared to the
56
augmented step acceleration.
This additional work helps explain the performance discrepancy between
the best quasi-Newton formulation and the best augmented Newton step formu-
lation in Figure (3.3). The other work that differs between the two approaches
includes the matrix inversion and several matrix-vector multiplications. Since
we have constructed M to be low rank, its inverse is less costly to produce.
However, this cost would certainly manifest for larger values of q.
Examining our regression risk estimate for diclofenac and GI bleeding, the
log relative risk that we recover is lower than some reported values. Reviews
of observational studies suggest the true relative risk diclofenac on upper GI
bleeding is near 3.98 with 95% confidence interval [3.36− 4.72], while our re-
covered relative risk is 1.19 with 95% confidence interval [1.02− 1.30][Gonzalez
et al., 2010]. While the fact that our method finds a significant positive associa-
tion between diclofenac and GI bleeding is encouraging, the risk estimates are
measurably different. There are several possible explanations for the discrep-
ancy. First, this is a penalized estimate, biasing our value toward 0, which is
consistent with underestimating the reported risk. Another possible result is
that significant difference in controlling for other exposures exists between this
study and those reported. Other research may not have controlled for as many
exposures as we have. Finally, observational datasets frequently represent very
different populations, with different group risk estimates. It is important to
note the challenge observational datasets poses. Unmeasured confounding
persistently complicates these results, our method may be unable to remove
all unmeasured confounding. We use one major observational data modalities:
claims data. These data are not collected for the scientific purposes. The claims
data reflect billing practices and are limited by insurance acceptance policies. It
is plausible that the source of bias from such collection is considerable.
In summary, the MM algorithm provides an elegant framework for devel-
oping optimization algorithms. However, integration of the MM algorithm
into the tools for observational healthcare analysis has been slow. The primary
concern is slow convergence in high-dimensional applications. Nevertheless,
the potential for this algorithm remains, and some have pushed through the
challenges in other disciplines [Zhou and Zhang, 2012, Zhou et al., 2010]. Our
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results highlight how an MM algorithm can improve speed fitting the SCCS
model at scale, shedding light on a new resource for computing in the setting
of massive observational data.
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CHAPTER 4
Diabetes Treatment Trajectories
Well-established guidelines anchor clinical treatment for diabetes mellitus type
II. However, characterizing actual treatment in practice is more elusive. To
our knowledge, little research illustrates how patients progress through drug
treatment regimens and how clinical tests alter these trajectories. We take
a step forward by examining insurance claims and electronic health records
data from four national datasets spanning 1994 to 2014, including a Medicare
subset, private insurance claims, and data from General Electric Centricity
users. This population consists of over 1 million patients who received at least
one diagnosis of T2D at some time in their medical history and have both
two hemoglobin A1c (HbA1c) tests and an oral anti-hyperglycemic mediation
in their observed history prior to any insulin initiation. Across patients, we
extract HbA1c measurements, the key justification for treatment intensification.
Following the framework of guideline recommendations, we track the number
of oral anti-hyperglycemic medications taken concurrently over the course of
each patient‘s history. We model this treatment count over time jointly with
most recent HbA1c status as a birth-death process, with first insulin use of
any formulation as a terminating state. We track the percent at 0, 1, 2, 3
or 4+ of drugs over time and count the patients who transition from high
to low HbA1c categories. We compute the transition rates between paired
drug count and HbA1c state, which represent treatment intensification and
de-intensification or response to treatment. We stratify by high/low persistent
HbA1c status and compare intensification rates. The relative proportion of
patients on 1,2,3, or 4+ drugs after a year on treatment stabilizes consistently
across datasets. Between 49% and 64% of patients remain in their initial HbA1c
state, independent of treatment. Furthermore, between 40% and 60% of patients
who start with high HbA1c never achieve low HbA1c, even transiently. Patients
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with perennially high HbA1c often show both faster intensification and de-
intensification. Therefore, we see that treatment impact on glycemic control
may be moderate; diabetes patients fail to intensify treatment along previously
recommended timelines; and poorly controlled patients struggle finding a
consistent treatment strategy.
4.1 Introduction
Clear treatment guidelines from both the American Diabetes Association (ADA)
and the American Association of Clinical Endocrinologists (AACE) direct man-
agement of diabetes mellitus type 2 (T2D) [Handelsman et al., 2015, American
Diabetes Association, 2015]. For a treatment naive patient, the initial ap-
proach is monotherapy, with metformin usually recommended. Failure to
meet hemoglobin A1c (HbA1c) goals triggers introduction of a second or third
treatment at three month intervals. Persistent failure to attain HbA1c goals
leads to insulin initiation.
Identifying how treatment intensification evolves in practice is more elusive
[Grimes et al., 2015]. Current approaches have been largely limited to cross-
sectional snapshots through longitudinal studies, surveys, and patient tracking
databases [Turner et al., 1999, Alexander et al., 2008, Hampp et al., 2014,
Dailey et al., 2002, Hazel-Fernandez et al., 2015]. The UK Prospective Diabetes
Study (UKPDS) followed patients every three months for three, six, and and
nine years post study initialization. From these patients, the UKPDS study
demonstrates that 50% of patients need an additional treatment to manage
their diabetes at three years, while 75% require an additional treatment at
nine years [Turner et al., 1999]. However, this was a structured, randomized
intervention, rather than an observation of real-world clinical data. To assay
the clinical experience, Alexander et al. [2008] examine the National Disease
and Therapeutic Index, a survey of office-based physicians selected by the
American Medical Association and the American Osteopathic Association
where the physicians report treatment patterns over two randomly sampled
consecutive days per quarter. The authors compare these mixed samples from
1994 to 2007. They find that the proportion of patients on monotherapy declined
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from 82% in 1994 to 47% in 2007.
Massive observational resources, including insurance claims and electronic
health records (EHRs) offer a new resource for understanding trajectories.
Observational datasets have become fertile resources for addressing questions
about diabetes in practice [Hampp et al., 2014, Grabner et al., 2013, Boccuzzi
et al., 2001, Dailey et al., 2002, Pladevall et al., 2004, Maclean et al., 2004, Grimes
et al., 2015, Slabaugh et al., 2015, Hazel-Fernandez et al., 2015, Weng et al., 2016].
Hampp et al. [2014] examine IMS Health Vector One National and Total Patient
Tracker databases for annual prescription use from 2003 to 2012. Like Alexander
et al. [2008], they are able to paint the trend in treatment using broad strokes.
They identify a rising use of non-insulin anti-hyperglycemics and a surprisingly
low rate of concomitant use of meformin with other treatment. Using eleven
data sources including claims and electronic health records (EHR) data with
a total of 250 million patients, Hripcsak et al. designed and implemented
an observational study to map out treatment trajectories without information
about how long a patient remains on a drug that the authors call pathways.
The authors found that 75% of patients started on metformin. However, only
29% of patients remained on metformin monotherapy. The prevalence of
persistent monotherapy varied dramatically across their data sources, from 10%
to 80%. The most striking result from their study is the combinatorial number
of potential treatment pathways observed.
While Hripcsak et al. quantify the diversity of diabetic treatment pathways,
they fail to capture the time component of treatment evolution. Among the few
studies that have considered time to treatment intensification is Berkowitz et al.
[2014]. They analyze the transition from monotherapy to dual therapy. They
sought to identify initial drug choices that are associated with an increased
hazard of treatment intensification. However, intensification may occur many
times during a patient’s history. Berkowitz et al. [2014] only illustrate the first
step of this process.
The challenge of identifying how patients traverse treatment choices shares
complexity and motivation with clinical pathway discovery, as in Huang et al.
[2013b] and Huang et al. [2013a]. However, while clinical pathway discovery
seeks to learn movement through the clinical system, we are more focused
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evaluating how diabetes patients receive treatment given the existence of a
solid, consistent system of guidelines. Recent work has offered new insight
into how answering this type of question may proceed in practice [Yoon et al.,
2013].
In the face of the little knowledge existing about treatment trajectories in
practice, there is an opportunity to learn about the full trajectory of treatment
intensification. This study defines a framework to begin this process. We focus
on oral anti-hyperglycemic medication for treatment intensification and treat
insulin initiation as a separate class of clinical outcome. The core structure for
our work will be the count of oral anti-hyperglycemic medication that a patient
takes over time. Particular medication choice often reflects individualized
clinical decision making. To accommodate this, the guidelines couch their
recommendations in overarching categories of monotherapy, dual therapy,
and triple therapy, while making softer recommendations for drug choices
within each category. We identify this flexibility as an asset. To allow for
patient-specific treatment choices, we echo the guidelines and focus on drug
count. In this framework, intensification is the addition of a medication, de-
intensification the subtraction of a medication. We want to understand how
intensification changes as a function of HbA1c measurements. The interplay
between HbA1c and treatment intensification is relevant and nontrivial, with
HbA1c being both the dominant trigger for intensification and the indicator for
treatment effectiveness. Finally, we will consider insulin use as an escape from
oral anti-hyperglycemic medication. That is, as soon as a patient begins using
insulin, we will consider insulin use to proceed indefinitely. We recognize that
different forms of insulin represent different treatment strategies, but we will
treat all insulin initiation as exchangeable.
We use observational data to approach the problem of treatment trajectories
from three directions. First, we report basic descriptive statistics of treatment
patterns through medical claims and electronic health record data tracking
1 million diabetic patients from four national databases. Second, we look
at the proportions of patients on different counts of oral anti-hyperglycemic
over time after treatment initiation. Third, we model the number of oral anti-
hyperglycemic medication a patient consumes as a Markov process, coloring
drug count states with high (H) or low (L) HbA1c status, and using first insulin
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use as an absorbing state. We then fit this model to evaluate and compare
intensification and de-intensification rates as functions of HbA1c level.
4.2 Methods
To learn about treatment in practice, we turn to four massive observational
healthcare databases maintained by the Reagan-Udall Foundation Innovation
in Medical Evidence Development and Surveillance (IMEDS) project. These
databases contain time-stamped patient data, including laboratory results, drug
exposures, and diagnoses, deidentified to compliance with the Health Insurance
Portability and Accountability Act of 1996 (HIPAA).
4.2.1 A diverse library of observational datasets
Three of these databases are from the Truven Health MarketScan Research
family of datasets. One of these datasets, the MarketScan Commercial Claims
and Encounters (CCAE) contains claims data from employees and their spouses
and dependents covered by employer-sponsored private health insurance,
including PPO and HMO plans, from inpatient and outpatient settings. The
MarketScan Medicare Supplemental and Coordination of Benefits database
(MDCR) includes inpatient and outpatient data from retirees with Medicare
supplemental insurance paid by employers. This dataset includes Medicare-
covered as well as employer or patient-covered expenses. The Medicare datasets
have a history of use in understanding diabetes treatment use, as in Grabner
et al. [2013], among others. Finally, the MarketScan Lab Database (MSLR)
includes patients with inpatient and outpatient records, with an additional
benefit of a high concentration of recorded laboratory results. We have access
to one electronic health record (EHR) dataset as well. This is the General
Electric Centricity Medical Quality Improvement Consortium (GECC) dataset.
It contains ambulatory EHR data from providers using the GE Centricity record
system who agree to share their data for research. Patients start their first
medication from 2005 to 2014, from 2005 to 2014, from 2004 to 2014, and from
1994 to 2014 for the CCAE, MDCR, MSLR, and GECC datasets, respectively.
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It is important to note the diversity of these datasets. We use the two major
observational data modalities: claims data and EHR data. This is relevant
because these data are not collected for the same purposes. The claims data
reflect billing practices, while the EHR data do not. The EHR data are limited
to clinical experiences where the EHR is deployed, while the claims data are
limited by insurance acceptance policies. It is not immediately clear that one
dataset is superior to another, but it is plausible that the sources of bias among
them differ. This offers us the chance to broaden our perspectives of the
problem at hand while lending credence to results shared among the datasets.
The development of a common data model (CDM) through the Observa-
tional Medical Outcomes Partnership (OMOP) experiment facilitates statistical
methods implementation using these data. The CDM allows us to address
pertinent questions about health practices, including comparative drug safety,
by standardizing data concept representation across resources [Overhage et al.,
2012]. Standardization takes the native representation in a clinical data set,
such as International Classification of Diseases version 9 (ICD-9), of concepts
like medication ingredients and diagnosis definitions, and translates them to a
common representation. This facilitates consistent and reproducible analysis
across datasets; we can apply the same analyses to each of these data resources,
without having to recode our approach to accommodate dataset-specific varia-
tions. We depend on the OMOP CDM version 4 for representation of concepts
of interest in all of our datasets.
One aspect of the OMOP CDM version 4 requires special attention. We use
the OMOP CDM 4 definition of a drug era. A drug era is a combination of
individual prescriptions or drug fills. For example, if the same medication is
refilled routinely at the end of its 30 day supply for 2 refills, this appears as
a single 90 day drug era. OMOP uses a standard 30 day persistence window,
where if a new supply of the same medication is given within 30 days of
the termination of a previous supply, it is considered the same era. For
example, consider a patient who takes metformin for 60 days, forgets to refill a
prescription for 4 days and does not take any medication. Then on the 5th day,
that patient refills the prescription and continues taking metformin for 90 days.
With a 30 day persistence window, all of the medication use actions result in
a single 154 day drug era. The 30 day persistence window helps buffer refill
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discontinuities.
4.2.2 The study population
To create our study populations, we begin by selecting all patients who ever
receive at least one diagnosis of T2D from each dataset, who are prescribed
at least one oral anti-hyperglycemic medication, and who have at least two
HbA1c measurements taken. Patients enter our study once they have had both
a drug era started and a HbA1c measured. For CCAE, MDCR, and MSLR,
96% of patient visits were in the outpatient setting, with 3% in the emergency
department (ED) and 1% in the inpatient setting. For GECC, 92% of visits were
outpatient, 5% were inpatient, and 3% were in the ED.
To understand the clinical background of the patients, we collect age at first
oral anti-hyperglycemic medication use, gender, HbA1c values, average serum
creatinine and albumin:creatinine ratio (ACR) over all samples, and the number
of statins ever used. We report the median, 25th, and 75th quartiles for each of
these clinical parameters. We report the percent of patients who ever receive
a diagnosis of cardiovascular disease (CVD), congestive heart failure (CHF),
hypertension (HTN), hyperlipidemia, kidney disease, eye disease, neuropathy,
or peripheral circulatory disorder. Although we rely on the OMOP CDM
version 4 concepts, we select diagnosis concepts based on ICD-9 codes. For
cardiovascular disease we used ICD-9 codes 410.*, 411.*, 412, 413.*, and 414.*.
For congestive heart failure, we used 398.91, 402.*, 404.*, and 428.*. Hyper-
tension and hyperlipidemia were identified with 401 and 272.*, respectively.
Kidney disease corresponded to codes 581.81, 583.81, and 585.* . Eye disease
corresponded to 362.07, 365.44, 366.41, and 369.*. Neuropathy consisted of
337.1, 353.5, 354.*, 355.*, 357.2,358.1, 396.54, 536.3, 713.5, and 782.0. Peripheral
circulatory disorder related to 250.7, 443.81, and 785.4.
For our study, we will treat HbA1c as ≥ 7 (high) or < 7 (low), rather than
as a continuous measurement. We do this to simplify the analysis. HbA1c of
7% reflects the value used in the UKPDS study and the ADA guidelines.
To have an overview of treatment trajectories, we extract summary statistics
characterizing over-arching treatment patterns in each of our datasets. First,
we consider the total time our patients are observable. We want to know
65
how long patients persist in our dataset. We report the median observation
time, where we define the median observation time as the total time each
patient spends covered in our data. As a proxy for how frequently clinical
interactions occur, we report median follow-up after the first treatment. We
define follow-up time as the time between initiation of therapy and a relevant
clinical event: a medication count change, a HbA1c measurement, insulin
initiation, or any clinical visit. We count the proportion of patients who ever
attain drug counts of 1, 2, 3, and 4 or more drugs during their time present in
the dataset. We extend the persistence window concept to drug counts, where
any pattern of de-intensification followed by intensification within 30 days is
ignored, and we consider the count persistent. This buffers our data against
mistaking medication switching with a de-intensification and intensification
pattern. Finally, we report the proportion of patients who fail to change HbA1c
status. These are the patients for whom all of their HbA1c measurements
consistently fall within the high or low categories.
Although we will not consider medication type in our study, we query the
percent of patients who have metformin as one of the treatments they receive
within the first day of treatment. This allows us to compare our treatment
initiation profile with that of Hripcsak et al.. Also, this helps orient us to how
closely the patients we observe follow the strong recommendation to begin
treatment with metformin.
We want to understand how patients progress through drug counts. To
do this, we look at the percent of patients on 0,1,2,3, or 4 or more drugs at 3
month intervals following the initial treatment era beginning for 10 years. Not
all patients persist for 10 years, and we show the percent extant patients from
the starting cohort.
4.2.3 Birth-death processes
Birth-death processes have a significant history of use modeling populations
[Kendall, 1948, Jaquette, 1970, Irvine et al., 1994]. When Kendall presents
generalized solutions to the birth-death process, the problem is framed in the
context of birth and death of individuals in a population [Kendall, 1948]. The
population of interest varies with application. Early populations of interest
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included infected individuals in epidemics [Becker, 1972]. More recently, the
populations of interest rely on clinical data. For example, Irvine et al. [1994]
uses a modified birth-death process to model geriatric patients navigating
in-patient resources. However, to the best of our knowledge, the application of
birth-death processes to model patient treatment trajectories is novel.
A birth-death process is a Markov process operating on a discrete space
over continuous time. State transitions only occur between neighboring states.
Considering a simple birth-death process over integer values j, for a state
j, one can only move from j to j + 1 (a birth) or j − 1 (a death). In many
modeling situations, j represents the count of an item of interest. The facility
of moving between states is captured by the transition rates, which measure
the probability of moving from one state to another in infinitesimal time.
0 1 2 3 · · ·
This simple model will form the skeleton of our approach. The states of
interest are the counts of oral anti-hyperglycemic medications consumed. We
extend this framework to capture some of the critical pieces to the clinical
puzzle. First, we include the interplay between the treatment intensification
and HbA1c. The guidelines make it clear that HbA1c should motivate clinical
decision making; high HbA1c should drive drug counts higher or inspire
faster progression to insulin use. However, increasing the number of diabetes
treatments should reduce the disease impact, driving down HbA1c. It is
possible to treat this interplay conditionally, looking at the count of drugs for
patients with high or low HbA1c. However, this approach misses the feedback
between HbA1c and drug treatments. We prefer to integrate HbA1c into the
birth-death model. We allow each drug count state to assume both a high and
low HbA1c level. This enables us to compare intensification / de-intensification
rates between drug counts across HbA1c status.
In this model, we are assuming that HbA1c is fully known over time and
stationary between observations, via the last observation carried forward. In
reality, we only have partial observations of the complete process. However,
we feel comfortable making this assumption because it represents the data
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Figure 4.1: The treatment trajectory for a 61 year old male patient from the MarketScan Lab
database (MSLR) over the course of observation. Each rectangle represents a single
drug era, with hemoglobin A1c (HbA1c) measurements shown as vertical bars. We
mark the part of his history that enters into our study with a red segment above
the measurement values.
available to the physician. That is, in between observations it is likely that the
physician refers to the last observed HbA1c. Therefore, we model the HbA1c
between observations as equal to the last observed HbA1c.
Figure 4.1 shows a 61 year old male patient from the MSLR dataset. While
the data tracks him from the first HbA1c measurement, he only enters into
our birth-death model once both his HbA1c status is established and his first
medication era begins. For him, this is shown with the red segment above his
history. This structure forces us to ignore the time prior to the first known
medication.
Second, we consider progression to insulin treatment separately from oral
anti-hyperglycemic medication. Progression to insulin treatment is often non-
reversible, with patients who begin insulin treatment often requiring insulin
for the rest of their disease duration. With this in mind, we will model insulin
initiation as an absorbing state. All treatment states can jump to the insulin use
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state, but no transitions exists from insulin.
Combining the insulin and HbA1c models together gives us our full model.
(0, L) (1, L) (2, L)
I
(0, H) (1, H) (2, H)
· · ·
· · ·
To keep track of this network of states, we need sufficiently general notation.
Since we are not just moving along a linear chain of possible states, the notions
of birth and death are less obvious. Let κm,n be the transition rate from state
m to state n. Let Dm be the set of possible destinations from m. If m = (1, L),
Dm = {(0, L), (1, H), (2, L), I} and κ(1,L),(2,L) is the transition rate for escalating
from one oral anti-hyperglycemic medications to two while remaining at low
HbA1c. We define Tm,n as the number of transitions from state m to state n and
Sm as the total time spent in state m. Because we are considering patients as
exchangeable and because the model is Markovian, we can sum all over all
patients and observations for a single T for each pair of states and a single S
per state.
4.2.4 Maximum likelihood estimates under the birth-death model
The likelihood under this model is well-known. Following Keiding [1975],
among many others, the likelihood is
L =
M
∏
m
e−(∑n∈Dm κm,n)Sm ∏
n∈Dm
κm,n
Tm,n ,
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and the log likelihood is
L =
M
∑
m
−( ∑
n∈Dm
κm,n)Sm + ∑
n∈Dm
Tm,n log κm,n.
We can compute the maximum likelihood estimate for the parameters. Taking
the derivative with respect to κp,q we find
∂L
∂κp,q
= −Sp + Tp,q
κp,q
Setting ∂L∂κp,q = 0 and solving yields intensification / de-intensification rate
estimates
κˆp,q =
Tp,q
Sp
.
To derive the asymptotic standard error, we compute the observed information
matrix. The diagonal elements are readily found as
− ∂
2L
∂κ2p,q
= − ∂
∂κp,q
(
−Sp + Tp,q
κp,q
)
=
Tp,q
κ2p,q
,
while the off-diagonal elements simplify to
− ∂
2L
∂κr,q∂κp,q
= − ∂
∂κr,q
(
−Sp + Tp,q
κp,q
)
= 0.
Inverting the observed information matrix and taking the square root gives the
standard error. Thus, for κˆp,q, the standard error is SE(κˆp,q) =
κp,q√
Tp,q
. Armed
with κˆp,q and its standard error, we can construct an asymptotic 95% confidence
interval as κˆp,q ± 1.96× SE(κˆp,q).
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Table 4.1: The demographic profile, including gender, age at the start of the study, comorbidities,
important clinical outcomes, and other medication use of the diabetic patients
included in the study from each of the datasets MarketScan Commercial Claims and
Encounters (CCAE), General Electric Centricity Medical Quality Improvement
Consortium (GECC), MarketScan Medicare Supplemental and Coordination of
Benefits Database (MDCR), and MarketScan Lab Database (MSLR)
CCAE GECC MDCR MSLR
n 114,060 757,135 27,073 133,042
Women (%) 46.6 51.7 48.3 47.1
Age (years) 55 [48,60] 61 [51,69] 71 [67,77] 56 [49,62]
Comorbidities
CVD (%) 21.4 19.1 38.9 24.4
CHF (%) 6.7 7.5 20.2 9.3
HTN (%) 71.3 55.3 87.1 73.6
Hyperlipidemia (%) 88.1 79.2 91.5 88.5
Kidney disease (%) 9.5 13.0 35.2 14.1
Eye disease (%) 2.2 1.1 5.2 2.8
Neuropathy (%) 26.1 14.7 34.8 27.2
Peripheral circ. 1.0 0.5 5.9 1.9
disorder (%)
Clinical outcomes
Hypoglycemia (%) 3.2 1.7 4.6 3.5
HbA1c 6.9 [6.3,7.9] 6.8 [6.2,7.6] 6.8 [6.3,7.5] 6.9 [6.3,7.8]
Serum creatinine 0.9 [0.7,1] 1 [0.8,1.2] 1 [0.8,1.3] 0.9 [0.8,1.1]
ACR 7 [4,18] NA 10 [5,30] 7 [4,20]
Other medications
Statins used 1 [1,2] 1 [1,2] 1 [1,2] 1 [1,2]
4.3 Results
We extract study populations from each of the four national databases, yielding
in total over 1 million T2D patients with at least one oral anti-hyperglycemic
claim or prescription and at least two HbA1c laboratory measurements. Table
4.1 offers a summary of the patient demographics and their health status.
4.3.1 Study population demographics
We begin with the general trends of drug use among patients, showing our
results in Table 4.2. Patients are present in our datasets for a median of 5
to 6 years. This reflects the entire time they are eligible for recording events.
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Table 4.2: A clinical treatment profile of the diabetic patients included in the study from each of
the datasets CCAE, GECC, MDCR, and MSLR. We show the median observation
length in the dataset and follow-up time from the onset of treatment, where follow-up
was defined as a clinical visit, a diabetes medication count change, a HbA1c test, or
progression to insulin. We report the percent of patients who start treatment with
metformin. We compute the percent of patients who ever reach a given count of
drugs, independent of time, in our data.
CCAE GECC MDCR MSLR
Median observation time (y) 5.9 5.1 5.1 5.6
Median follow-up time (d)
After first drug 20 30 16 19
Starting treatment (%)
Metformin 76.8 75.4 63.5 74.8
Proportion ever attaining drug count (%)
1 drug (%) 83.7 91.9 86.4 84.5
2 drugs (%) 53.2 52.4 48.8 52.8
3 drugs (%) 20.1 19.4 14.9 19.5
4+ drugs (%) 3.9 3.8 2.2 3.7
For all datasets, the overall median follow-up time from initiation of the first
treatment varied from 15 to 30 days. We defined the follow-up time as either a
relevant diabetes clinical event, including HbA1c measurement and medication
change, or a clinical visit for any reason. Our rational for these choices is that
each of these events represents an opportunity for physician-patient interaction
regarding treatment.
We also report an overview of treatment decisions. We find that roughly
75% of patients begin treatment with metformin, with the exception of the
MDCR data, where only 63.5% of patients begin treatment with metformin.
Additionally we examine the proportion of patients ever attaining a number of
medications. Specifically we count all patients who are on a medication for at
least one day at any point during their observation period. Roughly 50% of
patients will take two drugs concurrently at some point, and roughly 20% ever
take three drugs concurrently. However, the proportion of patients on 4 drugs
or more is less than 5%.
We also examine the dynamics of HbA1c testing across the datasets. In
Table 4.3, we see the median number of observations per person, the median
period of HbA1c testing, and the median time in between tests. Each patient
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Table 4.3: The hemoglobin A1c (HbA1c) testing profile of the diabetic patients included in the
study from each of the CCAE, GECC, MDCR, and MSLR datasets. We report the
time in days. For each quantity, we show the median and upper and lower quartiles.
CCAE GECC MDCR MSLR
Count HbA1c / person 4 [2,6] 6 [3,11] 5 [3, 7] 4 [2,6]
[median (Q1,Q3)] (%)
HbA1c testing period 472 223 365 410
median (Q1,Q3)] (%) [273, 803] [155,354] [212, 638] [247, 711]
Time between tests 134 129 139 135
[median (Q1,Q3)] (%) [92, 220] [95,195] [92, 209] [92, 218]
has, on average, 4 to 6 tests over her time in the study, and we have already
selected this population so that all patients have had at least two HbA1c tests.
The median period examines how many days occur in our study for each
HbA1c test. For all of the datasets, this ranges between half a year to a year
and a half per test. Similarly, we report the median time between tests. This
is the average time from one test to another, which differs from the median
period by not considering time between the study start and the first HbA1c test
or the time between the last HbA1c test and the study end.
We next turn to with the general trends of HbA1c dynamics among patients,
showing our results in Table 4.4. A remarkable result is the proportion of
patients who remain at either a high or low HbA1c state throughout the
duration of their observation. Collectively, across all datasets, between 49% and
64% of patients remain in their initial HbA1c state, independent of treatment.
Between 20% and 30% of patients remain in a high HbA1c state independent of
treatment. Similarly, between 29% and 40% of patients remain at a low HbA1c
state. Within the high HbA1c group, the median A1c values are 8.4, 8.1, 7.9,
and 8.3, and in the low HbA1c group, the median A1c values are 6.1, 6.1, 6.2,
and 6.1 for CCAE, GECC, MDCR, and MSLR, respectively.
We next turn to the relative breakdown of HbA1c events among patients
who start with high or low HbA1c. Specifically, we report the percent of
patients who start at high or low HbA1c and then the percent who move from
high to low, or high to low and back again, aggregating the group that makes
at least three such transitions. We show these results in Table 4.4. Between
40% and 60% of patients who start with high HbA1c never achieve low HbA1c,
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Table 4.4: These are a description of the HbA1c events among patients who start with high
or low HbA1c. We show the relative number of patients who remain stationary at
their HbA1c category, as well as the most frequent movement patterns. The percent
of patients starting at high versus low HbA1c is remarkably similar. Relatedly, all
of the datasets have largely consistent proportions of each transition type.
CCAE GECC MDCR MSLR
n 114,060 757,135 27,073 133,042
Start ≥ 7 (%) 49.1 50.2 58.8 50.7
Always ≥ 7 (%) 29.5 20.2 21.5 28.0
≥ 7→< 7 (%) 8.2 8.1 9.2 8.4
≥ 7→< 7→≥ 7 (%) 3.7 5.3 5.6 4.1
Other 2.9 7.7 4.5 3.3
Start < 7 (%) 50.9 49.8 41.2 49.3
Always < 7 (%) 34.3 29.1 39.5 35.0
< 7→≥ 7 (%) 12.5 12.5 10.6 12.2
< 7→≥ 7→< 7 (%) 5.5 7.3 5.1 5.5
Other 3.4 9.8 4.0 3.6
even transiently. In contrast, less than 20% make exactly one transition from
high HbA1c to low HbA1c. Relatively far more patients make the transition
from low HbA1c to high HbA1c one time.
4.3.2 Trends in medication count over time
Assessing the percent of people at given drug counts at three month follow up
intervals post initial treatment reveals that the distribution of medication counts
among the study patients changes rapidly in the first year, supplanted by much
more gradual change thereafter. We report these distributions in Figure 4.2. All
datasets show a similar rapid descent of the population of patients taking only
one drug, with an attendant rise in the percent of patients taking zero, two, or
three drugs. The percent of patients remaining on one drug hovers around 40%
for all datasets. For all but the GECC dataset, the next highest population is the
group of patients taking two drugs, whose proportion increases from roughly
20% within the first year toward 30% to 40% at 10 years. In the GECC dataset,
the patients taking zero drugs dominate, but their population steadily declines
from a peak near 40% within the first year after initial treatment initiation. The
absolute number of patients observed at each sample is strictly decreasing with
a super linear change.
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Figure 4.2: Tracking the distribution of patients at given counts of drugs over time after the
beginning of their first eras of treatment suggests a similar trajectory across each
of the MarketScan Commercial Claims and Encounters (CCAE), MarketScan
Medicare Supplemental and Coordination of Benefits database (MDCR), Mar-
ketScan Lab Database (MSLR), and General Electric Centricity Medical Quality
Improvement Consortium (GECC) datasets. In all datasets, the percent of patients
on one drug falls dramatically within one year, replaced by patients taking 0 or
2 drugs. After the initial recalibration, the proportion of patients at each count
changes slowly for the rest of observation.
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4.3.3 Full treatment trajectories
Turning to the results from our birth-death model, Figure 4.3 provides the first
full depiction of the treatment trajectory including HbA1c and insulin initiation.
The time spent in each state is proportional to the node size in our graph. For
the intensification / de-intensification rates, the edge thickness is proportional
to our maximum likelihood rates. Edge opacity is inversely proportional to the
standard error of the rates; rate estimates of which we are more certain appear
darker.
From the figure, we see that the time spent on 0, 1, and 2 drugs dominates
all the datasets, with time spent on 3 and 4 or more drugs appearing relatively
small. For most of the count states, the time spent in the low HbA1c category
appears higher than the time spent in the corresponding high HbA1c category.
Except for the zero to one transition, de-intensification rates appear higher than
intensification rates, but the intensification and de-intensification rates dwarf
the transition rates between the high and low HbA1c states and the transition
rate to insulin initiation.
Focusing on the patients who fail to change HbA1c status shown in Table
4.4 we recreate the plots from Figure 4.3, restricting ourselves to the patients
with perennially high or low HbA1c, which we treat separately. The resulting
plots are shown in Figure 4.4. Using the birth-death modeling framework,
we compare the 95% confidence intervals we constructed between the always
high and always low corresponding transition rate pairs for each dataset. A
red asterisk labels each of the transition arrows that is significantly higher
than its counterpart in the other group from the same dataset. Except for
three transitions in the GECC dataset, all of the asterisks label the high HbA1c
group of patients for each of the datasets. That is, for most intensifications,
de-intensifications, and transitions to insulin, the transition rates computed
using the population of patients whose HbA1c values are not seen falling below
7% are significantly higher than the corresponding rates for the patients whose
HbA1c values are not seen rising above 7%.
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Figure 4.3: Birth-death processes including high and low HbA1c status and insulin initiation
(I) for patients in the CCAE, GECC, MDCR, and MSLR datasets. Each of the
drug count states is a circle connected by arrows that reflect the rate of transition
between states. The size of the nodes is proportional to the time spent in drug
count state, {0, 1, . . . , 4+}, the edge widths are proportional to the maximum
likelihood transition rates, and opacity is inversely proportional to standard error.
Drug counts with high HbA1c status lie in the inner circle; those with low HbA1c
status remain further away from the central insulin node.
The time spent on 0, 1, and 2 drugs dominates all the datasets, with time spent on 3 and
4 or more drugs appearing relatively small. For most of the count states, the time spent
in the low HbA1c category appears higher than the time spent in the corresponding high
HbA1c category. De-intensification rates often appear higher than intensification rates.
Most notably, the intensification and de-intensification rates dwarf the transition rates
between the high and low HbA1c states and the transition rate to insulin initiation.
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4.4 Discussion
This research provides an emerging depiction of patient trajectories through
T2D treatment. Given the challenge of observational data, recovering patterns
that we expect can validate our conclusions. Beginning by examining our
patient cohort, we see trends that we naively expect. Considering Table 4.1, the
MDCR patients are generally older and have more comorbidities than their
counterparts from the other datasets. We expect medicare patients to represent
an older population compared to patients who have insurance through employ-
ers. Furthermore, it is reasonable that older patients have more comorbidities
on average than their younger counterparts.
The percent metformin use at treatment initiation is largely consistent with
previous findings [Hripcsak et al., Berkowitz et al., 2014, Grimes et al., 2015,
Weng et al., 2016]. The question remains why many patients begin on a drug
other than metformin. One reason might be that metformin is contraindicated
for some patients. Another reason might be treatment initiation outside of our
datasets. The short median observations times suggest that much of the patient
history exists outside of these datasets. Ultimately, this is a shortcoming of
decentralized claims and EHR data, where patients may pass in and out of the
isolated systems.
While our datasets contain inpatient, outpatient, and ED visit events, the
overwhelming majority of visits occur in the outpatient setting. This is reassur-
ing, since treatment decisions in the inpatient or ED settings may differ from
standard, long-term care approaches as an outpatient. Also, this underscores
the relevance of our results to clinicians working in an outpatient setting.
One of our most surprising findings is that there is a low level of transition
between the high and low HbA1c states. Half to two-thirds of the patient
population fails to change HbA1c status. This is unexpected for several reasons.
First, the population of patients at high HbA1c for the duration of their obser-
vation suggest that treatment with oral anti-hyperglycemic medication may be
ineffective at dropping the HbA1c of some patients below the 7% threshold.
Conversely, the patients who remain below 7% suggest that a population exists
whose disease course may be less severe, or for whom treatment may inhibit
disease course. Our estimates for low transition rates from high to low HbA1c
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are not isolated [Maclean et al., 2004].
Comparing the high and low HbA1c populations, intuition suggests that
the transition rates for intensification should be greater in the high HbA1c
population, and we recover this result. None of the intensification rates in the
low HbA1c population significantly exceed the corresponding rates in the high
HbA1c population. Similarly, the rates of transition to insulin in the low HbA1c
population never significantly exceed their counterpart rates in the high HbA1c
population. However, the de-intensification rates are also often higher for the
high HbA1c population.
High intensification and de-intensification rates together suggest that the
treatment states may be less stable for the high HbA1c patients. We could
be seeing the results of patients trying different medications. By moving
onto and off of different medication, patients would appear to have transient
intensification and de-intensification events. It is possible that we are seeing
issues of adherence. Patients who are poorly compliant would have a propensity
to both stop and restart medication regimens and have higher HbA1c. These
explanations are not mutually exclusive. In fact, our results may reflect a cycle
of frustration, absence of clinical response, and poor adherence, as frustrated
patients with high HbA1c that is resistant to treatment become less compliant.
Measuring adherence is challenging, but it has a notable impact on HbA1c
[Lawrence et al., 1970, Pladevall et al., 2004]. We ultimately do not know with
certainty when patients took medication, even if it was prescribed. This is an
inherent limitation of working with claims and EHR data. Future work should
create an independent compliance proxy and evaluate how that compliance
changes as a function of time for high HbA1c patients.
Poor follow up and compliance may not present the whole story. In par-
ticular, the median follow up times across the datasets are quite low. This
suggests that physicians and patients are communicating. While some of these
events are certainly not diabetes related, the frequency of follow up suggests
that physicians have the opportunity for intervention on patient treatment
trajectories. Phillips et al. [2001] discusses the phenomenon of clinical inertia,
where clinical treatment aggressiveness may be dampened in conditions where
treatment is not symptom motivated. Citing Harris et al. [1999], Phillips et al.
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[2001] report that only 33% of diabetic patients are adequately treated to lower
HbA1c below 7%, echoing our observed percent of patients who remain at high
HbA1c. This phenomenon has appeared before [Dailey et al., 2002, Slabaugh
et al., 2015].
Observational data are notorious for producing different results for different
databases [Madigan et al., 2014, 2013]. When different databases, with different
populations, show similar results, it is worth noting. Here, we see similar
trends for all the databases in Figure 4.2. After treatment initiation, all datasets
show that the percent of patients on a given medication count are similar
over time. Furthermore, the plateau level of patients on monotherapy hovers
between 40% and 60%, echoing the results of Alexander et al. [2008], Weng et al.
[2016]. Similarly, our reported levels of duel therapy may seem low. However,
the levels we see are very close to other studies; Qui et al. [2015, 2012] report
similar trends, despite looking exclusively at new users.
Clinically, this is really a cause for concern. The UKPDS study demonstrates
that 50% and 75% of patients will need an additional treatment to manage
their diabetes at 3 and 9 years, respectively [Turner et al., 1999]. The percent of
patients actually taking at least one additional medication at 3 and 9 years after
treatment initiation falls woefully short of 50% and 75%. This suggests that
clinicians may need to be more willing to intensify treatment than they show
in practice.
Insulin use rates are low. Compared to the rates of oral anti-hyperglycemic
medication, the rates of transition to insulin are markedly less. One obvious
explanation for this reticence is that there is a preference for avoiding insulin
on the part of the physicians and patients. 10-15 years used to be the standard
wait time between onset to insulin use, [Nathan, 2002]. Current guidelines
suggest at most 9 months between treatment initiation and insulin [American
Diabetes Association, 2015].
Working with observational data is inherently problematic, and many of
limitations apply here. First, all records relevant to each patient may not be
present in the dataset. For example, the GECC data reflects the prescriptions
written by a majority population of primary care physicians [Crawford et al.,
2010]. If a patient were to transfer care to a specialist, that patient might seem
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to disappear from our records. If this patient then reenters our dataset after
some time under the care of a specialist, it would seem that there were on no
treatments for a long time, when the reality may be far different. The shadow
of this limitation is visible in Figure 4.2. Specifically, in Figure 4.2, a much
larger percent of patients persist at 0 drugs over time in the GECC population.
This is possibly due to patients leaving the system for specialist care. However,
the percentages of patients remaining on monotherapy versus discontinuing
therapy actually have precedent in the literature [Hazel-Fernandez et al., 2015].
Some have offered economic reasons for departure from guidelines [Vigersky
et al., 2013].
Similarly, frequency of HbA1c testing depends on physician and patient,
and inadequate testing is not uncommon [Maclean et al., 2004]. Decisions to
test more or less frequently might alter our ability to draw conclusions from
this data. Future work should look closely at the relationship between going
on and off of a drug and the frequency of HbA1c testing and should be willing
to remove patients from our study who are insufficiently tested.
While it is concerning that the majority of patients appear to stop treatment
at some time, treatment changes are common [Boccuzzi et al., 2001]. This
is possibly a reflection of prescription era modeling decisions. The 30-day
persistence window is an arbitrary interval. It is still possible to observe
disjoint eras, when a single continuous era would be more clinically reasonable.
Medication may be taken sporadically, with some doses stored and then used
later. Future work should investigate how clinical information can better be
integrated into these drug eras.
Modeling the count of drugs introduces notable issues during medication
switching. In particular, if a patient changes from one medication to another,
this can enter the data as an erroneous intensification or de-intensification. For
example, if the patient switches midway through a prescription and receives
a secondary prescription, the overlapping eras will appear as a transient es-
calation to two drugs. Unfortunately, these issues are difficult to avoid in an
observational setting, when the only data we see are drug eras.
Another limitation of this study is the transformation of the HbA1c data
from a partially observed continuous process into a completely observed
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discrete process. The true HbA1c for a given individual moves stochastically
between observations, and it would be more meaningful to learn about this
process including the drug counts during the unobserved period. However,
we justify our approach by recognizing that we are in some sense modeling
the physician’s decision making, and it would be reasonable for a physician to
make treatment intensification decisions reliant on the last observed HbA1c
rather than the estimate of the current HbA1c. Future work will include
identifying the effect and importance of HbA1c cutoff and granularity. It is
reasonable to suspect that physician decision making as a function of HbA1c is
far more nuanced than branching on a high or low value.
Although the limitations of observational data are not to be underestimated,
one of the goals of this research is to highlight practice in a realistic clinical
setting. The questions of compliance and data completeness in our data
resemble the uncertainty of clinical decision making. Thus, in some sense,
the limitations of observational data force us to account for some of the same
uncertainties facing clinical decision makers. Our approach is a first step to
understanding the treatment trajectories of patients, offering insight into how
patients are treated and framing the conversation in terms of trajectories for
the first time.
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CHAPTER 5
Future Work
5.1 Markov chain Monte Carlo for SCCS at scale
Bayesian ideas have won approval in the setting of observational healthcare
data. Placing prior distributions over the estimates of relative risk for each
drug captures our belief that most drugs are safe and allows us to consider
related outcomes. In addition, using a Bayesian framework efficiently manages
challenges in estimation at scale [Madigan et al., 2011]. However, moving from
posterior mode estimates to extracting full posterior distributions is a standing
challenge in this setting.
5.1.1 Motivation
Current approaches for capturing uncertainty of our risk estimates for medical
interventions rely on bootstrapping. In bootstrapping, our goal is estimating
the standard error of a parameter of interest Efron and Gong [1983]. Bootstrap-
ping is a non-parametric approach. We approximate the standard error of a
parameter by estimating that parameter repeatedly using data resampled from
the full dataset with replacement. Although computationally intensive, it is
not prohibitive in the setting of observational healthcare data. In particular,
Suchard et al. [2013] bootstrap the mode estimates.
However, this approach is notoriously problematic. The Bayesian modeling
that we use is equivalent to a regularized regression framework, where our
prior distribution results in the penalization term. One particular example of
this is a Lasso penalized regression [Tibshirani., 1996]. The Lasso estimator
optimizes an l1 penalized regression. This regression corresponds to using
a Laplace prior in our formulation. There are two main benefits to using
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a Lasso penalized regression. First, it enforces sparse solutions, shrinking
small estimates to zero and producing a parsimonious model. Effectively,
this is simultaneous model selection and model fitting. Second, it allows for
computationally feasible inference [Tibshirani., 2004].
This shrinking effect is problematic when combined with bootstrapping.
Chatterjee and Lahiri [2010] consider bootstrapping a Lasso penalized linear
regression. They find that the bootstrap estimator converges weakly to a
random probability measure, rather than the target distribution. In particular,
their results show that the bootstrap is inconsistent when regression coefficients
are forced to zero. This is precisely the setting in which we expect our Lasso
penalized regressions to live. Chatterjee and Lahiri [2011] offer a modified
bootstrap approach to correct for this phenomenon.
However, a similar problem arises from selecting the hyperprior. To select
the hyperprior, the current best practice is to use cross-validation [Suchard
et al., 2013]. We use cross-validation based on the predictive log-likelihood of
the hold-out set to select the prior variance σ2 = 1τ . Suchard et al. [2013] use a
log-scale grid search that is computationally expensive even with only a single
parameter. To help overcome this burden, we turn to Genkin et al. [2007] in
implementing an “autosearch" for hyperparameter selection. We start with
an initial guess and then increase or decrease our guess by one log unit until
we have bracketed the maximum of the hold-out set predicted log-likelihood.
Then we compute a quadratic approximation to the predicted log-likelihood.
The maximum of this approximate surface becomes our estimate.
Ultimately, both the bootstrapping approach for estimator variability and
the predictive log-likelihood cross-validation approach for estimating the prior
variance fall short of capturing what our Bayesian framework really demands:
the full posterior distribution. In this project, we address these shortcomings
by developing fully Bayesian inference for SCCS using our massive datasets.
We address the challenges of dimensionality by exploiting model averaging.
We first simulate from the marginal posterior distribution of covariate inclusion
using a Laplace approximation. Next, we use Metropolis-within-Gibbs to learn
about both the drug relative risks given each covariate inclusion model and the
hyperprior variance. In the Metropolis step, we develop an adaptive indepen-
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dence sampler with proposals from a tuned multivariate normal distribution
around the mode estimate.
5.1.2 Methods
5.1.2.1 SCCS
In using the SCCS model, we follow the notation of Simpson et al. [2013] and
Suchard et al. [2013]. To revisit our nomenclature, the SCCS model assumes
that ADEs arise according to an inhomogeneous Poisson process. For j = 1 . . . J
drugs under consideration, the parameters β = (β1, . . . , β J)′ measure the
instantaneous log relative risks of treatment exposure. As before, let patients
i = 1, . . . , N have a baseline risk eφi and let the drug exposures multiplicatively
modulate the underlying instantaneous event intensity λik during constant
drug exposure era k. That is, the intensity arises as λik = eφi+x
′
ikβ, where
xik = (xik, . . . , xik)′ and xikj indicates exposure to drug j in era k for outcome
p. The exposure duration for exposure era k of patient i is lik. The number
of ADEs in era k of patient i is yik ∼ Poisson(lik × λik). The SCCS method
conditions on the total number of events for a particular outcome ni = ∑k yik
that a patient experiences over her total observation period. By conditioning
on these statistics, the baseline risk falls out of the conditional likelihood of the
data.
We place a prior distribution over each of the covariates
p(β|σ2) ∼∏
j
[
Normal
(
0,
1
σ2
)]
p(β|σ2) ∼∏
j
[
Laplace
(
0,
1
σ2
)]
.
(5.1)
As the model is currently formulated, we select the prior variance σ2 that
maximizes out of sample prediction through cross-validation. However, we
would like to place a distribution over this hyperprior and learn its value. We
start by making this adjustment to the hyperprior modeling. We place an
inverse-gamma distribution over our hyperprior variance σ2. This approach is
commonly used [George and McCulloch, 1993].
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5.1.2.2 Spike and slab prior
Variable selection is a long standing challenge [Ishwaran and Rao, 2005]. Some
approaches offer theoretically perfect model selection by considering all 2J mod-
els for J covariates, as compared in Shao [1997] among others. However, these
methods may fail in practice [Shao and Rao, 2000]. Furthermore, enumerating
2J for moderate J quickly become impractical.
One of the Bayesian solutions to this problem was the development of
spike and slab prior distributions [Mitchell and Beauchamp, 1988, George and
McCulloch, 1993]. Mitchell and Beauchamp [1988] designed the spike and slab
prior as a tool for selecting a subset of variables within a model. The core
idea of the spike and slab prior is a hierarchy of prior distributions over the
parameters and the model [Ishwaran and Rao, 2005]. Some model parameters
are vulnerable to exclusion, and that we would like the data to choose which
of these variables to remove. As such they allow covariates to have discrete
probability mass at zero. This discrete mass represents the “spike" component
of their name. Functionally, this component of the prior hierarchy is responsible
for model selection.
However, the non-zero covariates would still have a prior distribution over
them. Mitchell and Beauchamp [1988] maintain a diffuse prior distribution
over these non-zero values as well. This diffuse component of the prior is the
“slab" part of the name. This component is already built into the SCCS model;
the Normal and Laplace priors we currently use are functionally “slab" priors.
Our current model formulation is a degenerate case of the spike-and-slab prior
model - one without any spikes.
In the setting of observational healthcare data, using priors of this form is
reasonable. First, our prior distributions over the covariates are already centered
at zero, reflecting our belief that most diagnosis-intervention relationships are
null. Therefore, placing a point mass over zero merely underscores this belief.
Second, for any given adverse event, it is reasonable that most drugs will be
unrelated to it.
Given some shape and scale parameters κ and θ for our hyperprior distri-
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bution, our prior structure is now
σ2 ∼ Inv-Gamma(κ, θ) (5.2)
and
p(β|σ2) ∼∏
j
[
δ0(β j) +Normal
(
0,
1
σ2
)]
(5.3)
or
p(β|σ2) ∼∏
j
[
δ0(β j) + Laplace
(
0,
1
σ2
)]
. (5.4)
Note our use of δ0(β j), a delta function over β j to represent the point mass at
0 for β j. To capture our spike and slab prior, we consider the set of models
G = {g0, g1, ...g2J}, where gj represents the set of non-zero covariate values.
There are 2J possible models.
Gibbs sampling is commonly employed to learn about models with spike
and slab priors [George and McCulloch, 1993]. We follow the spirit of this
approach. But, to learn about our models, we use the Laplace approximation
to the posterior distribution, developed by Tierney and Kadane [1986]. In the
Laplace approximation, we use Laplace’s method to approximate our posterior
density. Laplace’s method relies on a second order Taylor expansion about
the posterior mode. Specifically, we find that the posterior is approximated by
a normal density centered at the posterior mode with a covariance equal to
minus the inverse hessian at the mode.
Armed with our cyclic coordinate descent framework, we have the tools nec-
essary for the Laplace approximation already in hand. Specifically, we already
compute the posterior mode βˆ. Computing the Hessian at βˆ is straightforward.
Under the SCCS model, the Hessian at the mode of model j is
∂2l(βj)
∂βj∂βj
=
N
∑
i
ni

 ∑Gig=1 tigex′igβjxig
∑Gig′=1 tig′e
x′
ig′βjxig′
⊗2 − ∑Gig=1 tigex′igβj (xig)⊗2
∑Gig′=1 tig′e
x′
ig′βj
 , (5.5)
where⊗ is the Kronecker product. Our covariance matrix for the approximating
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normal distribution is Σˆj. We construct
Σˆj = −
(
∂2l(βj)
∂βj∂βj
)−1
. (5.6)
Therefore we approximate the posterior distribution with N(βˆj, Σˆj).
Exploring the space of G = {g0, g1, ...g2J} is straightforward. We move
through the space of models by introducing or removing one variable at a time.
If we consider the current model gj and propose model gk, we accept gk with
probability
p =
Lgkpik
Lgjpij
(5.7)
where
Lgk =
L(βˆk)
(|Σˆk|2pi) 12
(5.8)
is the Laplace approximation likelihood and pij is the prior contribution for
model gj.
5.1.2.3 Metropolis-within-Gibbs
We will use Markov chain Monte Carlo (MCMC) to construct our posterior dis-
tribution. One of the great challenges of MCMC in high-dimensional problems
is poor mixing, or the slow convergence of an MCMC chain to a stationary
distribution. Many have tried to find solutions to this problem [Roberts and
Rosenthal, 2009]. However, this remains a challenge. For us, this is critical
when we are considering implementing MCMC to learn about models with
thousands to tens of thousands of parameters. Also, it is frustrating to be
limited by this dimensionality when we strongly believe that most parameters
will have negligible relevance for a given outcome of interest. By selecting
smaller models through the spike and slab prior, we mitigate some of the
dimensionality issues.
We will average over the models selected from the Gibbs-like process above.
Specifically, we will record the frequency with which each model is visited.
Then we will learn about the parameters included in a model given that model.
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Many Markov chain approaches are available to sample from our posterior
distribution. Two of the canonically dominant methods are the Metropolis-
Hastings algorithm and Gibbs sampling. While the method of choice for
exploring the posterior space should not alter the inevitable result, efficiency
of convergence is often the driving force in selecting one method over another.
Many have found that hybrid methods combing the Metropolis-Hastings al-
gorithm and Gibbs sampling emerge as the most efficient [Tierney, 1994]. We
follow in these footsteps by employing the Metropolis-within-Gibbs algorithm
[Metropolis et al., 1953, Tierney, 1994]. In particular, we will use this approach
to draw inference on our covariates given G.
In the Metropolis-within-Gibbs algorithm, we nest a Metropolis-Hastings
algorithm within a Gibbs sampler, learning about β and σ2 through two
dependent processes. We use the Metroplis-Hastings algorithm to learn about
P(β|Y ,X , σ2). To implement the Metropolis-Hastings portion, we use an
independence sampler for β with a normal transition kernel. Given a mode
estimate βˆ, we make a tentative draw of
β∗ ∼ N(βˆ, 1
τ
Σˆ), (5.9)
for positive τ. Following the standard form of the Metropolis-Hastings step,
we compute
r =
P(β∗|G,Y ,X , σ2)
P(βˆ|G,Y ,X , σ2) . (5.10)
To accept or reject this proposal, we define
δ = min(r, 1) (5.11)
and sample
u ∼ Uni f (0, 1). (5.12)
βt is accepted if δ is greater than a sampled u.
Mixing remains a concern. Adaptive Metropolis-Hastings algorithms are
designed to help with mixing problems [Roberts et al., 1997, Roberts and
Rosenthal, 2009]. We address this problem in our model by adaptively selecting
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a tuning parameter τ that scales the variance of the proposal distribution kernel.
Following Roberts et al. [1997], we strive for an acceptance frequency α around
0.25. Specifically, for MCMC iterate m, we tune τ as
τm = τm−1 +
1
1+
√
m
(αi − α). (5.13)
We learn about the hyperprior σ2 with the Gibbs sampler. Specifically, we
have modeled our hyperprior with an inverse Gamma distribution. Therefore,
we will sample the precision 1
σ2
from a Gamma(κ, θ) distribution. We define µ
as the mean of βˆ. For fixed constant κ0 and θ0, we draw
1
σ2
∼ Gamma(κ0 + N2 , θ0 +
1
2∑(βˆi−1 − µ)
2). (5.14)
After drawing 1
σ2
, we recompute βˆ using cyclic coordinate descent.
5.1.3 Demonstration
5.1.3.1 Synthetic study: small illustration
We look to validate our model with a small synthetic dataset that illustrates
the effectiveness of our approach. We simulate 1,000 patients exposed to 10
medical products. Among these products, 7 are safe, with log relative risks of
0. The other 3 products pose a risk to the simulated patients, with log relative
risks of 0.2. We structure the simulated data in this way to underscore why
model selection makes sense for comparative effectiveness and drug safety
surveillance studies. Most medical products have no effect on a given outcome
of interest. The true model of interest is therefore considerably smaller than
the full model.
βtruth = (0.2, 0, 0.2, 0, 0, 0, 0, 0, 0, 0.2)
′ (5.15)
We first find that the model selection chooses the most reasonable models
given our simulation framework. Showing the top 8 models, we see that model
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selection chooses, ordered by posterior density,
βG =

βg1 = (β0, 0, β2, 0, 0, 0, 0, 0, 0, β9)
′
βg2 = (β0, 0, β2, 0, 0, 0, 0, β7, 0, β9)
′
βg3 = (β0, β1, β2, 0, 0, 0, 0, 0, 0, β9)
′
βg4 = (β0, 0, β2, 0, 0, β5, 0, 0, 0, β9)
′
βg5 = (β0, 0, β2, 0, β4, 0, 0, 0, 0, β9)
′
βg6 = (β0, 0, β2, 0, 0, 0, 0, 0, β8, β9)
′
βg7 = (β0, 0, β2, 0, 0, 0, β6, 0, 0, β9)
′
βg8 = (β0, 0, β9, β3, 0, 0, 0, 0, 0, β9)
′
. . .
. (5.16)
Among the models shown, 92% of the density is placed on g1, the true model,
and the trail of models with less density are a single covariate inclusion away
from the true model, as seen in Figure (5.1). Notably, among the top 8 models,
none have dropped the 3 covariates that have true non-zero log relative risk.
g1 g2 g3 g4 g5 g6 g7 g8
Figure 5.1: The relative posterior density placed on the top 8 models selected using our Bayesian
model selection approach.
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Working with these smaller models facilitates the Metropolis-within-Gibbs
approach. To compare acceptance rates of our Metropolis-Hastings transition
kernel, we fix τ = 1. Under g f ull, even in this low dimensional setting, the
acceptance rate is 46%. As a comparison, under g1 the acceptance rate is 75%. In
the context of this toy synthetic data, these differences are irrelevant for overall
convergence. However, as the dimensionality of the problem increases, the
marginal benefit of using the model selection approach before the Metropolis-
within-Gibbs simulations offers greater potential merit.
5.1.3.2 Small real world study: bleeding events
We also test our approach on a small, real world example. Using the small
dataset introduced in Chapter 2, we revisit the problem of comparative risk
for dangerous bleeding events between warfarin or dabigatran etexilate. In
particular, we again examine the risk of gastrointestinal hemorrhage (GIH) and
intracranial hemorrhage (IcH). We do not use our hierarchical model, but rather
draw risk estimates ignoring the shared pathology. To perform these studies,
we again examine the MarketScan Lab Results (MSLR) dataset, maintained by
the Reagan-Udall Foundation Innovation in Medical Evidence Development
and Surveillance project. Using the OMOP common data model version 4 for
representation of concepts of interest, we collect all patients who experienced
a diagnosis of IcH or GIH. There are 37,909 patients who had GIH and 2,893
patients who had IcH.
We can compare the results from Figure (2.2) and Figure (5.2). Qualitatively,
a few trends are striking. First, both the bootstrap confidence intervals and
the marginal posterior distributions reflect the same risk patterns, namely,
warfarin shows the higher risk for IcH and the lower risk for GIH, relative
to dabigatran. However, the differences between the outcome-specific risk
distributions for warfarin are much more striking when looking at the marginal
posterior distributions.
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Figure 5.2: Marginal densities for the relative risk of dabigatran and warfarin for gastroin-
testinal hemorrhage (GIH) and intracranial hemorrhage (IcH) using the MSLR
dataset.
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5.1.4 Discussion
In this work, we leverage Bayesian model averaging to implement fully Bayesian
inference at the scale of observational healthcare data. We accomplish this by
averaging over covariate inclusion models. Then, given our model probabilities,
we learn the relative risks for each included covariate as well as the hyperprior
variance. Specifically, we rely on adaptive Metropolis-within-Gibbs.
There are many opportunities for improvement in this project. First, we
fail to include the graphic processing unit (GPU) mode finding strategy used
by Suchard et al. [2013]. For the model averaging component of the project,
mode finding remains the computational bottleneck. Therefore, using the GPU
implementation will have a significant effect on run time. Furthermore, there
are other opportunities for GPU parallelization in this project. In the mode
finding approach of Suchard et al. [2013], the log likelihood undergoes rank
one updates, as resetting all of the regression coefficients and recomputing the
log likelihood does not occur. However, in the Metropolis-Hastings method
we use, we frequently reset all of the β and recompute the log likelihood from
scratch. The computationally expensive component to this step is a sparse
matrix vector multiplication. We can implement this operation on the GPU as
well.
5.2 Non-parametric treatment intensification
Although modeling treatment intensification as a birth-death process helps to
elucidate the trajectory of patients through the space of oral anti-hyperglycemic
medication, the simple birth-death model that we use left much to be desired.
First of all, we did not provide a framework for learning about parameters
other than HbA1c. Comorbidities, concurrent treatments, and previous adverse
events could all reasonably alter treatment trajectory. For example, patients
with renal disease are often advised against taking metformin, otherwise the
first-line treatment of choice. Similarly, patients who experience hypoglycemic
events may avoid more aggressive treatment regimens. These clinically relevant
questions are beyond the scope our current approach. In a effort to mitigate
these shortcomings, we propose an approach to modify our birth-death model.
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5.2.1 Including covariates
Beginning with notation as before, let j index the states of the birth-death
process, the number of drugs a patient is taking. Let λj be the birth rate for
moving from j to j + 1 drugs. Similarly, let µj be the death rate of moving
from j to j− 1 drugs. To account for the edge conditions, define the maximum
number of drugs taken concurrently in a dataset as J. We enforce λJ = 0 and
µ0 = 0.
0 1 2
λ0
µ1
λ1
µ2
Before we start by considering covariates in our model, we are going to
introduce a toy dataset that we will use to illustrate how each of our methods
will be put to use. The graph in Figure (5.3) shows 3 example patient trajectories.
The time is in arbitrary units, and we disregard HbA1c status, focusing solely
on the drug count. Under the constant model, the likelihood is
L =e−(λ1+µ1)3µ1
× e−(λ1+µ1)4λ1 × e−(λ2+µ2)9λ2
× e−(λ1+µ1)5λ1 × e−(λ2+µ2)1µ2.
(5.17)
This allows us to estimate λˆ1 = 16 .
We want the transition rates to be non-parametric, multiplicatively modu-
lated by the covariates of interest. We begin by considering the Cox proportional
hazards model. In this model, the hazard function λ(t,x) is given by
λ(t,x) = λ0(t)ex
′β. (5.18)
Let the time to event T have density f (t,x) and distribution F(t,x). The
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Figure 5.3: This illustrates the treatment trajectories for 3 patients using oral anti-
hyperglycemic medication. These data will be central to the methods discussion of
integrating covariates.
survival function S(t,x) is
S(t,x) =
f (t,x)
1− F(t,x) =
f (t,x)
S(t,x)
. (5.19)
Equivalently,
S(t,x) = e−Λ(t,x) (5.20)
where
Λ(t,x) =
∫ t
0
λ(u,x)du. (5.21)
Let p index the patients. We start with a simple survival model. Consider
T = {t1, t2, . . . tP} the set of observed event times, one per patient. Let δp
indicate if tp is censored or not. δp = 0 if tp is a censored event. We only
consider right censoring.
The full likelihood under this model is
L(β) =∏
p
[ f (tp,xp)]δp [S(tp,xp)]1−δp
=∏
p
[λ(tp,xp)]δp [S(tp,xp)]
(5.22)
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But this is cannot be optimized because λ0(t) is unknown. So we use the partial
likelihood instead. To do this, we must introduce Qtp , the set of patients still
observed at tp. In the partial likelihood, we consider
Lpartial(β) =∏
p
[
λ(tp,xp)
∑q∈Qtp λ(tq,xq)
]δp
=∏
p
 λ0(tp)ex′pβp
∑q∈Qtp λ0(tq)e
x′qβq
δp
=∏
p
 ex′pβp
∑q∈Qtp e
x′qβq
δp
(5.23)
where the final step is made possible by canceling the underlying non-parametric
baseline hazard.
Two parts of the birth-death model are, in isolation, survival problems. In
particular, birth from the first state and death from the last state can be modeled
with the Cox proportional hazards model. Treating these steps independently,
for constant λ0 we substitute λ0,0(tp)ex
′
pβ1 . Similarly, for our simple model with
up to 2 drugs, we substitute λ2,0(tp)ex
′
pβ2 for µ2. Others have recognized that
the first step is a Cox proportional hazards model [Berkowitz et al., 2014].
Extending this insight, each of the other transitions emerge as separate
competing risks problems. That is, for each state other than the edge cases,
birth or death from that state represent competing events. An extension of the
Cox proportional hazards model exists for the competing risks framework. For
a model with k competing risks (causes), it is possible to have a cause-specific
hazard
λk(t,x) = λk,0(t)ex
′βk . (5.24)
Note that there are cause-specific covariates βk as well.
In the multiple cause scenario, we define S(t,x) as the probability of sur-
viving all types of events up to t. By analogy, we have
Sk(t,x) = e−Λk(t,x) (5.25)
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where
Λk(t,x) =
∫ t
0
λk(u,x)du. (5.26)
Denoting outcome kp as the outcome for person p, the total likelihood here is
L(β) =∏
p
[λkp(tp,xp)]
δp [S(tp,xp)]. (5.27)
Note that S(ti, xi) = ∏k Sk(ti,xi). Thus,
L(β) =∏
p
[λkp(tp,xp)]
δp∏
k
Sk(tp,xp)
=∏
p
∏
k
[λk(tp,xp)]
δp,k Sk(tp,xp)
(5.28)
where δp,k is a patient-outcome specific indicator such that δp,k = 1 if and only
if patient p experienced cause k.
This allows us to split the likelihood by cause type. Furthermore, for each
cause of interest, we treat the other causes as censored points. The partial
likelihood becomes
L(β|X ,T , δ) =∏
k
∏
p
[λkp(tp,xp)]
δp,k
∑q∈Qtk,p [λkq(tq,xq)]
δq,k
=∏
k
∏
p
[λkp,0(tp,xp)e
x′pβk ]δp,k
∑q∈Qtk,p [λkq,0(tq,xq)e
x′qβk ]δq,k
=∏
k
∏
p
 ex′pβk
∑q∈Qtk,p [e
x′qβk
δp,k
(5.29)
5.2.2 Non-parametric birth-death process
Having identified subproblems within our birth-death process formulation that
are amenable to non-parametric regression, we must still splice all of these
components together together. There are a few obstacles to this goal. First,
how we deal with time requires more consideration than in a single survival
or competing risk model. If we take the naive approach and use some metric
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∆tk,m the amount of time spent at state k in observation m, our baseline hazard
becomes a λk,0(∆tk,m). We loose the time dependent form that makes this
model desirable in the first place. Second, one of the assumptions underlying
the Cox proportional hazards model is the independence of observed survival
events. Using the offset per state approach, many observations will not be
independent, as patients will re-enter states and thus be present multiple times
in the analysis.
We solve these issues by left truncating. This technique is commonly used to
address staggered entrance into survival studies and is the preferable method
for accounting for different patient ages. For observation m, let the drug count
transition be at tm. Furthermore, let vm be the time at which observation m
began. In the Cox proportional hazards partial likelihood, we consider the set
of observations, Qtm , against which to compare observation m. Without left
truncating,
Qtm = {j : tj > tm}. (5.30)
With left truncating, we redefine
Qtm = {j : vj < tm < tj}. (5.31)
In other words, for each observation, we only compare it to the other observa-
tions whose time intervals contain tm. Looking at our toy data set in Figure
(5.3), we can recognize the transitions that can be evaluated and what their
comparator sets contain. The first transition that we include in our model
is the deescalation event of patient 1 from 1 drug to 0 drugs at time 3. The
comparator set for this event includes both patient 1’s own transition (an event)
and patient 2’s escalation to 2 drugs, which enters as a censored event. Notably,
patient 3 also makes the transition from 1 drug to 2 drugs, but this would not
enter into the comparator set because patient 3 is not extant at time 3. Patient 1
exists during patient 2’s transition from 1 to 2 drugs at time 4, but they do not
share a common state. Therefore, the transition from 1 to 2 for patient 2 does
not enter into our analysis. In fact, the only two transitions that enter into the
likelihood using left truncation from the toy dataset are the transition from 1 to
0 in patient 1 and the transition from 2 to 1 in patient 3.
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Left truncation solves both problems listed above. First, we are no longer
using the offset time from arrival to each state. Therefore, the model treats time
universally. This allows the baseline hazard rate functions to be meaningfully
interpreted. Second, a single patient cannot be at the same state during
overlapping times. Therefore, we avoid the problem of dependence among the
observations within each patient.
5.2.3 Dimensionality
Using our large observational datasets poses a dimensionality problem. Specifi-
cally, we need to draw inference on the effects estimates for all covariates of
interest for each transition. That is, while βk,k+1, the regression covariates for
transitioning from k to k + 1, is large, β = [β0,1, . . . ,βK−1,K,βK,K−1, . . . ,β1,0 is
much larger. However, we have already developed a framework for dealing
with problems like this in Chapter 2. We can consider using the hierarchical
prior. This is medically reasonable because similar covariates should similarly
affect time spent in each state.
Our sample size was notably reduced with left truncation in the toy dataset,
as we went from 5 included transitions to 2. This will certainly be problematic
for small datasets. Our large datasets come to our rescue. Because of our
conditioning arguments, the number of patients in any given denominator
will be small relative to the total number of patients in the dataset. With too
little data, the number of overlapping intervals may be too small to perform
any analysis. Therefore, we may only be able to fit this model because we are
working in a high dimensional setting. This is a somewhat unique approach
in that it succeeds only in the setting of massive amounts of data. We are
empowered to use left truncation, the more rigorous approach, strictly because
of the setting in which we are drawing inference.
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